Professor Andrew Zannettino

Professor of Experimental Haematology

Adelaide Medical School

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Andrew Zannettino is the Associate Dean of Research and Professor of Experimental Haematology in the Faculty of Health Sciences, University of Adelaide and heads the Myeloma Research Laboratory (MRL) and co-heads the Regenerative Medicine Program (RMP).

The MRL’s efforts centre on identifying the molecular and cellular mechanisms responsible for myeloma disease progression and myeloma-associated bone loss.

The RMP stems from collaborative studies in association with Prof Stan Gronthos (Mesenchymal Stem Cell Laboratory, University of Adelaide) and Prof Paul Simmons (Mesoblast Ltd), which led to the patenting of technologies covering the identification and isolation of Mesenchymal Precursor Cells (MPC), a rare cell population present in many post-natal tissues.

The family of 8 patents surrounding this technology underpin the world’s largest cell therapy company, Mesoblast Ltd.

My Research
Career
Publications
Grants and Funding
Teaching
Supervision
Professional Activities
Contact

Research Interests

Myeloma is haematological malignancy characterised by the clonal proliferation of plasma cells, an immune cell type that normally protects us against infection. Myeloma is the second most common blood cancer and more than 100,000 people are diagnosed each year worldwide. Despite recent advances in treatment, myeloma remains almost universally fatal and has a 10-year survival rate of approximately 17%. The main clinical manifestations of myeloma are the development of osteolytic bone lesions, bone pain, hypercalcaemia, renal insufficiency, suppressed immunoglobulin production and increased bone marrow angiogenesis (blood vessel formation). Myeloma is preceded by a premalignant (asymptomatic) monoclonal gammopathy of uncertain significance (MGUS) stage. The factors that trigger the progression from MGUS to myeloma remain to be determined; however, our studies show that both intrinsic genetic changes and extrinsic factors play a role in disease progression. Our laboratory’s research is focussed on detecting the key signalling pathways that are deregulated during disease development and determining what microenvironmental changes occur during disease pathogenesis. We believe that these approaches will enable us to identify new molecular markers of disease risk and to design drugs against novel therapeutic targets.

Current projects are focused on

Identifying the genetic, transcriptional and epigenetic changes that trigger the progression from asymptomatic MGUS to myeloma
Determining why the bone marrow is a “hot-spot” for myeloma plasma cell metastasis
Identifying the mechanisms governing dissemination and relapse in multiple myeloma
Identifying the role played by the newly described tumour suppressor genes GLIPR1 and SAMSN1 in multiple myeloma development
Determining the effects of myeloma plasma cells on mesenchymal stem cell differentiation.
Assessing the effectiveness of targeting class IIa histone deacetylases (HDAC) to treat myeloma and myeloma-associated bone disease
Identifying the role of the mTOR pathway in mesenchymal stem cell biology and bone formation.
Assessing the effectiveness of targeting skeletal mTORC1 as a novel approach to treat diet-induced insulin resistance

Research Leadership

I provide research leadership as Associate Dean (Research), Faculty of Health Science and Laboratory Leader, Myeloma Research Laboratory, Cancer Theme, SAHMRI. As detailed herein, I also provide research leadership as a board member of a number of Institutes and Centres, member of the Assigners Academy of the NHMRC and committee member of the Medical and Scientific Advisory Group of the Australian Myeloma Foundation.

Myeloma and Bone Cancer Research

Multiple myeloma is an incurable haematological cancer of the antibody-producing plasma cell. Myeloma is unique amongst haematological malignancies in its capacity to cause massive destruction of the skeleton. The Myeloma Research Laboratory’s (MRL) efforts centre on identifying the molecular and cellular mechanisms responsible for myeloma disease progression (https://www.sahmri.com/our-research/themes/cancer/groups/mel-test-group).

The MRL has made a significant contribution to the field in relation to

Mechanisms of myeloma associated bone loss
Identifying the genetic, transcriptional and epigenetic changes that trigger the progression from asymptomatic MGUS to myeloma
Determining why the bone marrow is a “hot-spot” for myeloma plasma cell metastasis
Identifying the mechanisms governing dissemination and relapse in multiple myeloma
Identifying the role played by the newly described tumour suppressor genes GLIPR1 and SAMSN1 in multiple myeloma development
Identifying how myeloma plasma cells affect mesenchymal stem cell differentiation.
The effectiveness of targeting class IIa histone deacetylases (HDAC) to treat myeloma and myeloma-associated bone disease
Identifying a role for the mTOR pathway in mesenchymal stem cell biology and bone formation.
Assessing the effectiveness of targeting skeletal mTORC1 as a novel approach to treat diet-induced insulin resistance

Therapeutic Use of Mesenchymal Progenitor Cells

Mesenchymal Progenitor Cells (MPC) are rare stem cells present within post-natal tissues which possess promising therapeutic properties. In the late 90’s, collaborative studies in association with Prof Stan Gronthos (Mesenchymal Stem Cell Laboratory, UA/SAHMRI) and Professor Paul Simmons (Mesoblast Ltd.) led to the patenting of technologies covering the identification and isolation of these rare cells from bone marrow. The family of 8 patents surrounding this technology were assigned to Angioblast Systems Inc., New York, USA in November, 2004 facilitating the formation of Mesoblast Ltd, an Australian Stock Exchange listed company (http://www.mesoblast.com). In return for the assignment of these patents, the IMVS/Medvet/SA Pathology (my substantive employer at that time) received a significant parcel of shares in this company. Since January 2005, Prof Gronthos and I have served as consultants to both Angioblast Systems Inc. and Mesoblast Ltd. and our laboratories have continued to receive funding to support the improvement/development of existing/new intellectual property and to fund large pre-clinical animal models of disease.

Research Collaborations

My expertise in the fields described above has led to active collaborations with scientists/clinicians throughout the world as detailed below.

In 1994-1995, I developed a powerful retroviral-based expression cloning strategy to enable isolation of genes encoding cell surface molecules that participate in intercellular interactions. This methodology has lead to numerous collaborations and ongoing consultation work with scientists including:

Dr H-J. Buhring, University of Tubingen, Germany, Retroviral Expression cloning of cell surface antigens expressed by normal and leukaemic haemopoietic stem cells;
Prof. Leonie K. Ashman, University of Newcastle, Retroviral Expression cloning of drug resistance genes;
Prof. James T. Triffit, Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Oxford, UK, Retroviral Expression cloning of osteoblast-related cell surface antigens;
Dr S. Watt, MRC Molecular Haematology Unit, The Institute of Molecular Medicine, University of Oxford, UK, Retroviral Expression cloning of novel cell surface molecules.

My research into myeloma-associated bone loss and molecular mechanisms of myeloma disease pathogenesis has led to further collaborations with a number of academic and industry-based scientists including:

Prof. John Shaughnessy, Formerly of University of Arkansas, Little Rock, Arkansas, USA and founder of SignalGenetics^TM, Carlsbad, CA. The role of DKK-1 in myeloma-associated bone loss;
Dr Daniel Peet, Department of Bichemistry, Molecular Life Sciences, University of Adelaide: Role of CXCL12 (SDF-1)/CXCR4 in Pathological Angiogenesis and Osteolytic Bone Disease in Multiple Myeloma;
Dr Phil Kearney, Santaris Pharma, Copenhagen, Denmark: Role of CXCL12 (SDF-1)/CXCR4 in Pathological Angiogenesis and Osteolytic Bone Disease in Multiple Myeloma;
Prof. Nobutaka Fujii and Prof. Hirokazu Tamamura, Graduate School of Pharmaceutical Sciences Kyoto University Department of Bioorganic Medicinal Chemistry, JAPAN, Role of SDF-1 in myeloma;
A/Prof. Kevin Lynch, Novartis, Sydney, Australia, Tyrosine Kinase Inhibition as a Potential Modality to Control Osteolytic Bone Disease: A New Role for Imatinib Mesylate and Second Generation Bcr-Abl Inhibitors;
Dr Elisabeth Buchdunger and Dr Paul Manley, Novartis Pharma, Skeletal Effects of the Abl Kinase Inhibitors, Nilotinib and Imatinib;
Dr Francis Lee and Dr Richard Smykla, Bristol-Myers Squibb, Skeletal Effects of the Abl Kinase Inhibitors, Dasatinib;
Prof. Vijay Modur, Novartis Pharmaceuticals Corporation, Cambridge, MA, USA. Novel mediators of multiple myeloma metastases to the bone;
Prof. William Dougall, Amgen, Seattle, Washington, USA, The role of RANKL in myeloma-associated bone loss;
Prof. Peter Croucher, Bone Biology Laboratory, Bone Biology Division, Garvan Institute of Medical Research, NSW, AUS. The role of the bone marrow microenvironment in the pathogenesis of myeloma;
Dr Daniel Worthley, University of Adelaide, Adelaide, Australia, The role of the bone marrow microenvironment in the pathogenesis of myeloma;
Prof. Siddhartha Mukherjee, Columbia University, NY, USA. The role of the bone marrow microenvironment in the pathogenesis of myeloma;
Prof. Orest Blaschuk, Urology Research Laboratories, Division of Urology, McGill University Health Centre, Canada. The use of Cadherin antagonists to treat multiple myeloma;
Prof. Jonathan Licht, University of Florida Cancer Centre. The role of EMT in myeloma disease dissemination and disease progression;
Prof. Ricky Johnstone, Gene Regulation Laboratory, Peter MacCallum Cancer Centre, The role of the bone marrow microenvironment in the pathogenesis of myeloma;
Associate Professor Simon Leedham, Wellcome Trust Centre for Human Genetics, Oxford, The role of the bone marrow microenvironment in the pathogenesis of myeloma;
Prof. Charles Mullighan, Hematological Malignancies Program, St. Jude Children’s Research Hospital, Understanding clonal evolution in multiple myeloma;
Prof. Gareth Morgan, University of Arkansas, Myeloma Institute for Research and Therapy (UAMS), Understanding clonal evolution in multiple myeloma.

My research into physiological and aberrant bone remodelling and novel skeletally-derived factors that regulate glucose metabolism has led to collaborations with a number of academic and industry-based scientists including:

Prof. D.M. Findlay and Dr Gerald J. Atkins and Dr. Andreas Evdokiou, Discipline of Orthopaedics and Trauma, Royal Adelaide Hospital and the University of Adelaide. Normal and pathological bone remodelling;
Dr. Andreas Evdokiou, Discipline of Surgery, Basil Hetzel Institute for Translational Health Research and the University of Adelaide. Bone cancer and bone cancer metastasis;
Dr Colin Dunstan, University of Sydney and formerly of Amgen Inc, CA, USA; The Role of OPG in bone metabolism;
Dr Peter J Anderson and Prof David David, Child Health Research Institute and The Women’s and Childrens Hospital, Adelaide, South Australia: Mechanisms of premature cranial fusion and development of novel adjunct approaches to treatment;
Prof H. Zreiqat, School of Pathology, University of New South Wales, Sydney, Australia, Behaviour of osteoclasts and bone cells on bio-material surfaces;
Prof D. R. Haynes, Department of Pathology, University of Adelaide, Adelaide, South Australia, The role of TNF family members TWEAK and TNF-alpha in bone remodelling;
A/Prof Sofianos Andrikopoulos, The University of Melbourne, The University of Melbourne, Skeletal endocrine signalling in the regulation of glucose metabolism;
Dr Paul Baldock, Garvan Institute of Medical Research, Garvan Institute of Medical Research, The University of New South Wales, Skeletal endocrine signalling in the regulation of glucose metabolism;
Prof Christopher Proud, South Australian Health and Medical Research Institute, SA, AUS, Targeting skeletal mTORC1 as a novel approach for the treatment of diet-induced insulin resistance.

My research into mesenchymal precursor cell biology and application has led to collaborations with a number of biotechnology companies, including Angioblast Systems Inc., Mesoblast Ltd. and Genzyme International. In addition, I also collaborate and consult for a number of academic scientists including:

Prof. Silviu Itescu, University of Melbourne and Columbia University's New York -Presbyterian Hospital in New York, USA and Angioblast Systems Inc and Mesoblast Ltd.: Clinical Application of Mesenchymal Precursor Cells for bone repair, articular cartilage regeneration, disc cartilage regeneration, cellular therapy of heart attack/heart failure, peripheral arterial disease and wound ulcers;
A/Prof. Robert Moore, Formerly head of the Adelaide Centre for Spinal Research, Institute of Medical and Veterinary Science, Adelaide, South AUSTRALIA: A Preclinical trial of the potential for cultured mesenchymal precursor cells to restore extracellular matrix and normal mechanical function to degenerate intervertebral discs;
Prof. Peter Ghosh, Institute of Nutraceutical Research, Brookevale, NSW, Australia: Cartilage Regenerative Potential of Ovine Mesenchymal Precursor Cells (MPC);
A/Prof John Field, Flinders University of South Australia, School of Medicine, Bedford Park, South Australia: Evaluation of the safety and efficacy of Allogeneic Mesenchymal Progenitor Cells (MPC) for the repair of critical size defects in an ovine tibial model;
Prof. Stephen Worthley, Cardiovascular Investigation Unit, Royal Adelaide Hospital, Adelaide, South Australia: A study of the cardiac regenerative potential of immunoselected ovine bone marrow mesenchymal stem cells;
Dr Cory Xian and Prof. Bruce Foster, Bone Growth Foundation, Department of Orthopaedic Surgery, Women's and Children's Hospital. Molecular pathways for the bony repair of injured growth plate cartilage;
Prof. Richard Read, Evaluation of the safety and efficacy of Allogeneic Mesenchymal Progenitor Cells (MPCs) in the regeneration of a medial knee joint meniscus and the retardation of cartilage injury in an ovine model of osteoarthritis;

Since 2005, I have been a scientific consultant for Mesoblast Ltd. where I have helped consolidate and expand our stem cell based technology patent family and have successful completed key milestones such as the development of a MSC isolation and culture expansion standard operational protocol within a GMP facility. This has resulted in an increase in capital investor funding to support the commencement of several phase II/III cardiac and orthopaedic clinical studies. Funds from Mesoblast Ltd have been used to continue basic R&D in our laboratory and for initiating new pre-clinical animal studies within the IMVS/ Hanson Institute/ RAH/ University of Adelaide campuses. Collectively, these studies have formed the foundation of new IND (investigative new drug) applications submissions to the USA FDA for future phase I/II/III human clinical trials involving different health centres and laboratories in Adelaide, Australia and the USA.

Research Output

I have co-authored more than 177 refereed publications, book chapters and review articles (not including published abstracts). Many of these articles are published in premier Haematology and Orthopaedic journals (BLOOD, Leukemia, BJH, JBMR, Bone), Cancer journals (Cancer Research, Clinical Cancer Research) and Stem Cell journals (Cell Stem Cell, Stem Cells). My publications have received in excess of 9800 citations and his H Factor = 51. Refer to Publications section for full details.

Presentations

I have has been invited to present my laboratory’s findings at more than 40 national and international forums since 2010. In addition, I have co-authored more than 75 abstracts with more than 55 of these being published as Meeting Proceedings.

Conference Presentations
Year	National/ International	Event Title	Role
2016	National	New Directions in Leukaemia Research meeting March 16-19, 2016, Noosa, QLD, AUS	Invited Speaker
2015	International	"PACIFICHEM 2015 Conference December 15-20, 2015 in Honolulu, HI."	Invited Speaker
2014	International	American Society of Haematology	Invited Speaker
2014	National	Sydney Cancer and Bone Meeting	Invited Speaker
2013	International	Australian and New Zealand Bone and Mineral Society	Invited Speaker
2013	National	Frontiers in Skeletal Biology	Invited Speaker
2012	National	Combio 2012	Invited Speaker
2012	National	SA Multiple Myeloma Interest Group	Invited Speaker
2012	National	SVRI-Seminar Series	Invited Speaker
2012	National	The Australian Health and Medical Research Congress	Invited Speaker
2011	International	Austalian and New Zealand Bone and Mineral Research	Plenary Speaker
2010	National	Adelaide Bone Group Meeting	Invited Speaker
2010	International	American Society of Haematology	Session Chair
2010	National	Annual HSANZ - SA “Blood Club Meeting”,	Invited Speaker
2010	National	Leukaemia Foundation of Australia – Myeloma Awareness Day	Invited Speaker
2009	International	Asia Pacific Haematology Summit	Keynote Speaker
2009	International	HAA 2009; 2009 Annual Scientific Meeting of HSANZ, ANZSBT, ASTH	Keynote Speaker
2009	National	Health Development Adelaide Symposium	Presenter
2009	International	Janssen Cilag, Multiple Myeloma 3 (MM3) meeting	Presenter
2009	International	Novartis APECHO-APTM Workshop	Keynote Speaker
2008	International	American Society of Haematology	Poster Presenter
2008	National	Bio Innovation SA Networking Forum – Bio Innovation Osteo Networking Evening	Keynote Speaker
2008	International	Fifth Clare Valley Bone Meeting	Keynote Speaker
2008	National	NCRIS 5.5 CGMP - SEMINAR/WORKSHOP - “NANO-ENGINEERING FOR CELLS”	Presenter
2008	National	Royal Adelaide Hospital Medical Grand Round	Presenter
2007	National	Barbara Ell Seminar Series, Victor Chang Cardiac Research Institute	Presenter
2007	International	Novartis Oncology Research and Development Symposium	Presenter
2007	National	2007 Mater Medical Research Institute Symposium	Presenter
2006	International	American Society of Haematology	Session Chair
2006	National	Department of Orthopaedics and Trauma, Royal Melbourne Hospital	Presenter
2006	National	Inaugural Tissue Engineering Symposium (SuTEN), Biomedical Engineering at Sydney University School of Aerospace, Mechanical and Mechatronic Engineering and The Bosch Institute	Presenter
2006	International	Novartis Oncology Australia, Research and Development Symposium, The Intercontinental Hotel	Keynote Speaker
2005	National	ANZ Matrix Biology Society Conference, Whalers Inn, Victor Harbour, SA	Keynote Speaker
2005	National	Department of Genetic Medicine, Womens and Children’s Hospital	Presenter
2005	National	Division of Molecular Pathology, IMVS	Presenter
2005	National	The Basil Hetzel Institute, The Queen Elizabeth Hospital	Presenter
2004	International	Haematology Society of Australia and New Zealand, Exhibition and Convention Centre	Presenter
2003	National	Adelaide Blood Club	Invited Speaker
2003	National	Division of Clinical Biochemistry, IMVS	Invited Speaker
2003	National	Division of Molecular Pathology, IMVS	Invited Speaker
2003	National	Division of Pathology, IMVS	Invited Speaker
2003	National	The Alfred Hospital	Invited Speaker
2002	International	Australian and New Zealand Orthopaedic Research Society	Invited Speaker
2002	National	Child Health Research Institute	Invited Speaker
2002	National	Department of Medicine, University of Adelaide	Invited Speaker
2002	National	Molecular Biology of Skeleton	Invited Speaker
2001	National	Adelaide Blood Club	Invited Speaker
2001	International	Molecular Mechanisms of Skeletal Disease mediated by Myeloma, NIH	Invited Speaker
2001	International	Zymogenetics	Invited Speaker
1998	International	Australian and New Zealand Orthopaedic Research Society	Invited Speaker
1998	International	Haematology Society of Australia and New Zealand	Invited Speaker
1998	National	Hanson Symposium	Invited Speaker

Additional Evidence of Research Leadership

When I joined the UA School of Medical Sciences (SoMS), I served as a member of the Research Committee. In January 2014, I was appointed as Chair of this committee, and immediately instituted 4 new funding programs designed to drive research activity, including an ECR “kick start” award, a strategic equipment fund, an ECR/MCR travel award and a publication award program.

I was also appointed to the SoMS board, the FHS Research Committee and was the Deputy Chair of the Adelaide Medical and Nursing School (AMNS) Project Committee overseeing the construction of a new $230 million Medical/Nursing/Research facility in the new West End Biomedical Research Precinct which will house approximately 350 Researchers. In January 2015, I was appointed to Deputy Head, SoMS. In March 2015, the Executive Dean, Professor Alastair Burt appointed me to establish and chair the Research Strategy Taskforce (RSTF). The RSTF was charged with the responsibility of devising a new research strategy to promote research excellence within the FHS. This work has led to the development of an adaptable strategic framework to enhance research education (HDR/honours), develop research strengths, build enabling technologies/research infrastructure and develop pathways to improved health care and the generation of valuable intellectual property.

My national standing in the fields of cell and cancer biology has been recognised by my appointment to the NHMRC Grant Review Panel (GRP) for Cell biology (2005, 2006) and Oncology (2010) and Assigners Academy (2014, 2015, 2016). In recognition of my international standing in the field of myeloma-associated bone loss, I was invited by the Leukaemia Research Fund (LRF) of UK, to participate in a “site visit” of Myeloma Program of Prof. Peter Croucher, University of Sheffield, UK, to assess his application for program funding through the LRF in both 2006 and 2009. In addition, I was invited to participate as a moderator for the 2006 American Society of Haematology (ASH) Annual Meeting, for the session titled “Multiple Myeloma: Microenvironment”. Recently, I was invited to be an Abstract Reviewer of the “Myeloma-Pathophysiology and Preclinical studies excluding Therapy” Category for the 52^nd Annual Meeting of the ASH, a prestigious appointment bestowed upon recognized experts in the field.

As a testament to my expertise in my chosen fields, I have been asked to present my laboratories findings at numerous scientific meetings and institutions (see “Conference Presentations”) and I have been asked to contribute to numerous review articles and book chapters (see “Publications”). As a recognised expert in the areas of skeletal, stem and cancer biology, I am asked to review >3 manuscripts per month for more that 20 journals including BLOOD, Leukemia, Leukemia and Lymphoma, Experimental Hematology, Haematologica, Journal of Bone and Mineral Research, Leukemia, Cell Stem Cell, Clinical Cancer Research, Cancer Research, International Journal of Cancer, Bone, FASEB Journal. I am also regularly asked to review applications for a number of funding bodies including the NHMRC, Cancer Council of South Australia, Cure Cancer Australia and Leukaemia Research Fund (UK). Most recently, I was approached by the Wiley-Blackwell publishing house to assess the merits of publication of a book entitled: “Stem Cells: Science and Business Strategies” by A. Vertes et al.

As further evidence of my scientific standing, I have served on organising committees involved in staging both national and international scientific meetings including; the 2004 Hanson Symposium Stem Cell Meeting (Adelaide, SA, 2004); the 10th International Myeloma Congress (Sydney, NSW, 2005); the Clare Bone Meeting (Clare Valley, SA, 2006). I represented the Centre for Cancer Biology (CCB) as a Subject Matter Expert (SME) charged with the role of identifying the facilities requirements for the South Australian Health and Medical Research Institute (SAHMRI). Finally, I have served on the Fellowships and Scholarships Committee for the Leukaemia Foundation of Australia.

Clinical Outcomes of Research

As a member of MSAG, I have provided guidance on both myeloma and supportive treatment strategies and have co-authored guidelines for the safe use of bisphosphonates (Dickinson M et al, Intern Med J. 2009. May;39(5):304-16) and Clinical Practice Guidelines (Quach H et al, in preparation, 2010). Furthermore, my work has raised the awareness amongst clinicians of the importance of routine examination of CTX levels in patients. CTX (the C-telopeptide of the α1 chain of collagen type 1), a reliable marker of bone turnover, is now being used locally as a routine test for all myeloma patients at diagnosis and restaging. CTX, when used in conjunction with paraprotein levels and bone marrow assessment can detect early progression of myeloma. This is a palpable achievement and one that has led to better outcomes for patients.

As a co-inventor of the Mesenchymal Progenitor Cell (MPC) cellular therapy, I have been instrumental in developing a therapy that is likely to have a significant impact in the areas of spinal fusion, osteoarthritis, congestive heart failure, heart attacks, eye diseases, diabetes, and bone marrow repair.

Patents

I am a co-inventor of 8 patents that describe the isolation and composition of matter of mesenchymal precursor cells (MPC), a unique population of adult stem cells with tissue reparative properties. This family of patents were assigned to Angioblast Systems Inc., New York, USA in November, 2004 facilitating the formation of Mesoblast Ltd, an Australian Stock Exchange listed company. In 2010, Mesoblast acquired Angioblast Systems Inc forming the Mesoblast Group.

Patents
Year	Patent Number	Patent Office	Status
2008	US 61/189,349	United States of America	Under Examination
2006	PCT/AU2006/000494	United States of America	Under Examination
2004	PCT/AU2005/001445	United States of America	Granted
2004	PCT/AU2005/000953	United States of America	Granted
2003	WO 2004/085630	United States of America	Granted
2003	WO 2004/084921	Australia	Granted
1999	WO 01/04268A1	United States of America	Granted
1997	WO9707204	United States of America	Granted
1997	JP9188700	Japan	Granted

Expand

Appointments

Date	Position	Institution name
2015	Principal Senior Research Fellow	SAHMRI
2012	Associate Dean, Research	University of Adelaide
2012	Professor of Experimental Haematology	University of Adelaide
2011	Affiliate Professor	University of Adelaide
2010	Chief Medical Scientist and Head of the Research Unit	SA Pathology / Institute of Medical and Veterinary Science
2010	ASH Abstract Reviewer	American Society of Haematology
2008 - 2012	Research Manager	SA Pathology/Institute of Medical and Veterinary Science
2008 - 2012	Co-Head, Regenerative Medicine Program	Institute of Medical and Veterinary Science
2007 - 2012	Chief Medical Scientist, Laboratory Head and Research Manager	SA Pathology/Institute of Medical and Veterinary Science
2007 - 2010	Affiliate Associate Professor	University of Adelaide
2006 - 2012	Head of the Myeloma Research Program	Institute of Medical and Veterinary Science
2005	Site reviewer	University of Sheffield, Leukemia Foundation - United Kingdom
2004 - 2006	Principle Medical Scientist and Laboratory Head	Institute of Medical and Veterinary Science/Hanson Institute
2000 - 2003	Senior Medical Scientist	Institute of Medical and Veterinary Science/Hanson Institute
1997 - 1999	NH&MRC Research Officer	Institute of Medical and Veterinary Science

Awards and Achievements

Date	Type	Title	Institution Name	Country	Amount
1999	Award	Young Investigator Award	Hanson Centre for Cancer Research	Australia	—
1998	Award	Johnson and Johnson Young Investigator award	Australian and New Zealand Orthopaedics Research Society	Australia	—
1992	Award	Postgraduate Scholarship Award	University of Adelaide	Australia	—

Education

Date Institution name Country Title
1997 University of Adelaide Australia PhD
1992 University of Adelaide Australia Honours (First Class)
1991 University of Adelaide Australia BSc (Hons)
Research Interests

Cancer Biology and Clinical Oncology Translational Health Outcomes Innovative Therapeutics

Date	Institution name	Country	Title
1997	University of Adelaide	Australia	PhD
1992	University of Adelaide	Australia	Honours (First Class)
1991	University of Adelaide	Australia	BSc (Hons)

Expand

Journals

Year	Citation
2019	Cakouros, D., Hemming, S., Gronthos, K., Liu, R., Zannettino, A., Shi, S., & Gronthos, S. (2019). Specific functions of TET1 and TET2 in regulating mesenchymal cell lineage determination 06 Biological Sciences 0601 Biochemistry and Cell Biology 06 Biological Sciences 0604 Genetics 11 Medical and Health Sciences 1103 Clinical Sciences. Epigenetics and Chromatin, 12(1), 20 pages. DOI
2019	Arthur, A., Nguyen, T., Paton, S., Zannettino, A., & Gronthos, S. (2019). Loss of EfnB1 in the osteogenic lineage compromises their capacity to support hematopoietic stem/progenitor cell maintenance. Experimental Hematology, 69, 43-53. DOI
2018	Dutta, A. K., Hewett, D. R., Fink, J. L., & Zannettino, A. C. (2018). Using genomics to better define high-risk MGUS/SMM patients.. Oncotarget, 9(93), 36549-36550. DOI
2018	Martin, S., Fitter, S., El Khawanky, N., Grose, R., Walkley, C., Purton, L., . . . Zannettino, A. (2018). mTORC1 plays an important role in osteoblastic regulation of B-lymphopoiesis. Scientific Reports, 8(1), 1-10. DOI
2018	Mrozik, K., Blaschuk, O., Cheong, C., Zannettino, A., & Vandyke, K. (2018). N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. BMC Cancer, 18(1), 1-16. DOI Scopus3 WoS1 Europe PMC1
2018	Zysk, A., DeNichilo, M., Zinonos, I., Hay, S., Liapis, V., Ponomarev, V., . . . Panagopoulos, V. (2018). Zoledronate Enhances the Cytotoxicity of Gamma Delta T Cell Immunotherapy in an Orthotopic Mouse Model of Osteolytic Osteosarcoma. Journal of Cancer Science and Therapy, 10(9), 262-266. DOI
2018	Dutta, A., Fink, J., Grady, J., Morgan, G., Mullighan, C., To, L., . . . Zannettino, A. (2018). Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia. DOI Scopus1
2018	Arthur, A., Nguyen, T., Paton, S., Klisuric, A., Zannettino, A., & Gronthos, S. (2018). The osteoprogenitor-specific loss of ephrinB1 results in an osteoporotic phenotype affecting the balance between bone formation and resorption. Scientific Reports, 8(1), 12 pages. DOI
2018	Camp-Dotlic, E., Pribadi, C., Anderson, P., Zannettino, A., & Gronthos, S. (2018). miRNA-376c-3p mediates TWIST-1 inhibition of BMSC osteogenesis and can reduce aberrant bone formation of TWIST-1 haploinsufficient calvarial cells. Stem Cells and Development, 27(23), 1621-1633. DOI
2018	Zhang, J., Yun, S., Bi, J., Dai, S., Du, Y., Zannettino, A., & Zhang, H. (2018). Enhanced multi-lineage differentiation of human mesenchymal stem/stromal cells within poly(N -isopropylacrylamide-acrylic acid) microgel-formed three-dimensional constructs. Journal of Materials Chemistry B, 6(12), 1799-1814. DOI Scopus1 WoS1
2018	Camp, E., Anderson, P., Zannettino, A., Glackin, C., & Gronthos, S. (2018). Tyrosine kinase receptor c-ros-oncogene 1 inhibition alleviates aberrant bone formation of TWIST-1 haploinsufficient calvarial cells from Saethre-Chotzen syndrome patients. Journal of Cellular Physiology, 233(9), 7320-7332. DOI Scopus2 WoS2 Europe PMC1
2018	Markides, H., McLaren, J., Telling, N., Alom, N., Al-Mutheffer, E., Oreffo, R., . . . El Haj, A. (2018). Translation of remote control regenerative technologies for bone repair. NPJ Regenerative medicine, 3(1), 1-12. DOI
2018	Paisitkriangkrai, S., Quek, K., Nievergall, E., Jabbour, A., Zannettino, A., & Kok, C. (2018). Co-fuse: a new class discovery analysis tool to identify and prioritize recurrent fusion genes from RNA-sequencing data. Molecular Genetics and Genomics, 293(5), 1217-1229. DOI
2018	Fitter, S., & Zannettino, A. (2018). Osteopontin in the pathophysiology of obesity: Is Opn a fat cell foe?. Obesity Research and Clinical Practice, 12(3), 249-250. DOI
2018	Daly, C., Ghosh, P., Zannettino, A., Badal, T., Shimmon, R., Jenkin, G., . . . Goldschlager, T. (2018). Mesenchymal progenitor cells primed with pentosan polysulfate promote lumbar intervertebral disc regeneration in an ovine model of microdiscectomy. Spine Journal, 18(3), 491-506. DOI Scopus3 WoS1 Europe PMC1
2018	Tangseefa, P., Martin, S., Fitter, S., Baldock, P., Proud, C., & Zannettino, A. (2018). Osteocalcin-dependent regulation of glucose metabolism and fertility: Skeletal implications for the development of insulin resistance. Journal of Cellular Physiology, 233(5), 3769-3783. DOI Scopus2 WoS1 Europe PMC1
2017	Vandyke, K., Zeissig, M., Hewett, D., Martin, S., Mrozik, K., Cheong, C., . . . Zannettino, A. (2017). HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1. Cancer Research, 77(20), 5452-5463. DOI Scopus5 WoS4 Europe PMC1
2017	Hewett, D., Vandyke, K., Lawrence, D., Friend, N., Noll, J., Geoghegan, J., . . . Zannettino, A. (2017). DNA barcoding reveals habitual clonal dominance of myeloma plasma cells in the bone marrow microenvironment. Neoplasia : An International Journal for Oncology Research, 19(12), 972-981. DOI Scopus1 Europe PMC1
2017	Wu, J., Shimmon, S., Paton, S., Daly, C., Goldschlager, T., Gronthos, S., . . . Ghosh, P. (2017). Pentosan polysulfate binds to STRO-1+mesenchymal progenitor cells, is internalized, and modifies gene expression: A novel approach of pre-programing stem cells for therapeutic application requiring their chondrogenesis. Stem Cell Research and Therapy, 8(1), 15 pages. DOI
2017	Camp, E., Anderson, P., Zannettino, A., & Gronthos, S. (2017). Tyrosine kinase receptor c-ros-oncogene 1 mediates TWIST-1 regulation of human mesenchymal stem cell lineage commitment. Bone, 94, 98-107. DOI Scopus5 WoS4 Europe PMC4
2017	Panagopoulos, V., Liapis, V., Zinonos, I., Hay, S., Leach, D., Ingman, W., . . . Evdokiou, A. (2017). Peroxidase enzymes inhibit osteoclast differentiation and bone resorption. Molecular and Cellular Endocrinology, 440(C), 8-15. DOI Scopus2 WoS3
2017	Zysk, A., DeNichilo, M., Panagopoulos, V., Zinonos, I., Liapis, V., Hay, S., . . . Evdokiou, A. (2017). Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer. Cancer Letters, 386, 141-150. DOI Scopus4 WoS3 Europe PMC3
2017	Cantley, M., Zannettino, A., Bartold, P., Fairlie, D., & Haynes, D. (2017). Histone deacetylases (HDAC) in physiological and pathological bone remodelling. Bone, 95, 162-174. DOI Scopus6 WoS5 Europe PMC6
2017	Hemming, S., Cakouros, D., Codrington, J., Vandyke, K., Arthur, A., Zannettino, A., & Gronthos, S. (2017). EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture & structural integrity and accelerates remodeling. FASEB Journal, 31(3), 1011-1027. DOI Scopus9 WoS8 Europe PMC9
2017	Nguyen, T., Arthur, A., Zannettino, A., & Gronthos, S. (2017). EphA5 and EphA7 forward signaling enhances human hematopoietic stem and progenitor cell maintenance, migration, and adhesion via Rac1 activation. Experimental Hematology, 48, 72-78. DOI Scopus2 WoS1 Europe PMC1
2017	Fitter, S., Gronthos, S., Ooi, S., & Zannettino, A. (2017). The mesenchymal precursor cell marker antibody STRO-1 binds to cell surface heat shock cognate 70. Stem Cells, 35(4), 940-951. DOI Scopus7 WoS7 Europe PMC5
2017	Fitter, S., Matthews, M., Martin, S., Xie, J., Ooi, S., Walkley, C., . . . Zannettino, A. (2017). mTORC1 plays an important role in skeletal development by controlling preosteoblast differentiation. Molecular and Cellular Biology, 37(7), e00668-1-e00668-20. DOI Scopus9 WoS5 Europe PMC7
2017	Talaulikar, D., Tam, C., Joshua, D., Ho, J., Szer, J., Quach, H., . . . Prince, H. (2017). Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 47(1), 35-49. DOI Scopus4 WoS2 Europe PMC3
2017	Vuckovic, S., Vandyke, K., Rickards, D., McCauley Winter, P., Brown, S., Mitchell, T., . . . Hutchinson, A. (2017). The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells. British Journal of Haematology, 177(3), 423-440. DOI Scopus6 WoS4 Europe PMC5
2017	Wallington-Beddoe, C., Bennett, M., Vandyke, K., Davies, L., Zebol, J., Moretti, P., . . . Pitson, S. (2017). Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget, 8(27), 43602-43616. DOI Scopus6 WoS7 Europe PMC7
2017	Dutta, A., Hewett, D., Fink, J., Grady, J., & Zannettino, A. (2017). Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. British Journal of Haematology, 178(2), 196-208. DOI Scopus3 WoS4 Europe PMC3
2017	Harrison, S., Mollee, P., Roberts, A., Talaulikar, D., Brown, R., Augustson, B., . . . Zannettino, A. (2017). Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Internal Medicine Journal, 47(8), 938-951. DOI Scopus6 WoS4 Europe PMC3
2017	Liapis, V., Zysk, A., DeNichilo, M., Zinonos, I., Hay, S., Panagopoulos, V., . . . Evdokiou, A. (2017). Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma. Cancer Medicine, 6(9), 2164-2176. DOI Scopus2 WoS3 Europe PMC1
2016	Whittaker, J., Dutta, N., Zannettino, A., & Choudhury, N. (2016). Engineering DN hydrogels from regenerated silk fibroin and poly(N-vinylcaprolactam). Journal of Materials Chemistry B, 4(33), 5519-5533. DOI Scopus4 WoS4
2016	Ebert, L., Tan, L., Johan, M., Min, K., Cockshell, M., Parham, K., . . . Bonder, C. (2016). A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis. Angiogenesis, 19(4), 463-486. DOI Scopus5 WoS5 Europe PMC3
2016	Nguyen, T., Arthur, A., Paton, S., Hemming, S., Panagopoulos, R., Codrington, J., . . . Gronthos, S. (2016). Loss of ephrinB1 in osteogenic progenitor cells impedes endochondral ossification and compromises bone strength integrity during skeletal development. Bone, 93, 12-21. DOI Scopus5 WoS4 Europe PMC4
2016	Arthur, A., Cakouros, D., Cooper, L., Nguyen, T., Isenmann, S., Zannettino, A., . . . Gronthos, S. (2016). Twist-1 enhances bone marrow mesenchymal stromal cell support of hematopoiesis by modulating CXCL12 expression. Stem Cells, 34(2), 504-509. DOI Scopus7 WoS6 Europe PMC6
2016	Liapis, V., Zinonos, I., Labrinidis, A., Hay, S., Ponomarev, V., Panagopoulos, V., . . . Evdokiou, A. (2016). Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models. Cancer Medicine, 5(3), 534-545. DOI Scopus7 WoS8 Europe PMC8
2016	Freeman, B., Kuliwaba, J., Jones, C., Shu, C., Colloca, C., Zarrinkalam, M., . . . Howell, S. (2016). Allogeneic mesenchymal precursor cells promote healing in postero-lateral annular lesions and improve indices of lumbar intervertebral disc degeneration in an ovine model. Spine, 41(17), 1331-1339. DOI Scopus13 WoS11 Europe PMC4
2016	Bhattacharya, S., Chalk, A., Ng, A., Martin, T., Zannettino, A., Purton, L., . . . Walkley, C. (2016). Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death. Oncogene, 35(40), 5282-5294. DOI Scopus19 WoS19 Europe PMC13
2016	Walia, M., Ho, P., Taylor, S., Ng, A., Gupte, A., Chalk, A., . . . Walkley, C. (2016). Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance. eLife, 5(2016), e13446-1-e13446-31. DOI Scopus11 WoS10 Europe PMC7
2016	Hemming, S., Cakouros, D., Vandyke, K., Davis, M., Zannettino, A., & Gronthos, S. (2016). Identification of novel EZH2 targets regulating osteogenic differentiation in mesenchymal stem cells. Stem Cells and Development, 25(12), 909-921. DOI Scopus10 WoS8 Europe PMC8
2015	Weber, N., Mollee, P., Augustson, B., Brown, R., Catley, L., Gibson, J., . . . Prince, H. (2015). Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 45(4), 371-382. DOI Scopus10 WoS9 Europe PMC5
2015	Mrozik, K., Cheong, C., Hewett, D., Chow, A., Blaschuk, O., Zannettino, A., & Vandyke, K. (2015). Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma. British Journal of Haematology, 171(3), 387-399. DOI Scopus11 WoS8 Europe PMC6
2015	Nguyen, T., Arthur, A., Panagopoulos, R., Paton, S., Hayball, J., Zannettino, A., . . . Gronthos, S. (2015). EphB4 expressing stromal cells exhibit an enhanced capacity for hematopoietic stem cell maintenance. Stem Cells, 33(9), 2838-2849. DOI Scopus13 WoS10 Europe PMC11
2015	Liapis, V., Labrinidis, A., Zinonos, I., Hay, S., Ponomarev, V., Panagopoulos, V., . . . Evdokiou, A. (2015). Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. Cancer Letters, 357(1), 160-169. DOI Scopus20 WoS17 Europe PMC16
2015	Quach, H., Joshua, D., Ho, J., Szer, J., Spencer, A., Harrison, S., . . . Prince, H. (2015). Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group (vol 45, pg 335, 2015). INTERNAL MEDICINE JOURNAL, 45(6), 690. DOI
2015	Quach, H., Joshua, D., Ho, J., Szer, J., Spencer, A., Harrison, S., . . . Prince, H. (2015). Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: Position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 45(1), 94-105. DOI Scopus4 WoS5 Europe PMC3
2015	Mollee, P., Roberts, A., Horvath, N., Talaulikar, D., To, B., Zannettino, A., . . . Prince, H. (2015). Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 45(3), 335-343. DOI Scopus1 WoS1
2015	Noll, J., Vandyke, K., Hewett, D., Mrozik, K., Bala, R., Williams, S., . . . Zannettino, A. (2015). PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. Journal of Hematology and Oncology, 8(1), 106-1-106-16. DOI Scopus10 WoS9 Europe PMC9
2015	Lawson, M., McDonald, M., Kovacic, N., Khoo, W., Terry, R., Down, J., . . . Croucher, P. (2015). Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nature Communications, 6(1), 8986-1-8986-15. DOI Scopus73 WoS67 Europe PMC60
2015	Martin, S., Fitter, S., Dutta, A., Matthews, M., Walkley, C., Hall, M., . . . Zannettino, A. (2015). Brief report: The differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation. Stem Cells, 33(4), 1359-1365. DOI Scopus37 WoS35 Europe PMC34
2015	Cakouros, D., Isenmann, S., Hemming, S., Menicanin, D., Camp, E., Zannetinno, A., & Gronthos, S. (2015). Novel basic helix-loop-helix transcription factor hes4 antagonizes the function of twist-1 to regulate lineage commitment of bone marrow stromal/stem cells. Stem Cells and Development, 24(11), 1297-1308. DOI Scopus12 WoS11 Europe PMC11
2015	Martin, S., Gan, Z., Fitter, S., To, L., & Zannettino, A. (2015). The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Leukemia Research, 39(3), 380-387. DOI Scopus16 WoS16 Europe PMC13
2015	Cheong, C., Chow, A., Fitter, S., Hewett, D., Martin, S., Williams, S., . . . Vandyke, K. (2015). Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 332(1), 24-38. DOI Scopus8 WoS8 Europe PMC6
2015	Gupte, A., Baker, E., Wan, S., Stewart, E., Loh, A., Shelat, A., . . . Walkley, C. (2015). Systematic screening identifies dual PI3K and mTOR Inhibition as a conserved therapeutic vulnerability in osteosarcoma. Clinical Cancer Research, 21(14), 3216-3229. DOI Scopus18 WoS15 Europe PMC18
2015	Baker, E., Taylor, S., Gupte, A., Sharp, P., Walia, M., Walsh, N., . . . Walkley, C. (2015). BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. Scientific reports, 5(1), 10120-1-10120-14. DOI Scopus46 WoS39 Europe PMC35
2015	Forristal, C., Brown, A., Helwani, F., Winkler, I., Nowlan, B., Barbier, V., . . . Levesque, J. (2015). Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML. Leukemia, 29(10), 2075-2085. DOI Scopus14 WoS15 Europe PMC11
2015	Nguyen, T., Melville, A., Nath, S., Story, C., Howell, S., Sutton, R., . . . Revesz, T. (2015). Bone marrow recovery by morphometry during induction chemotherapy for acute lymphoblastic leukemia in children. PLoS One, 10(5), e0126233-1-e0126233-10. DOI Scopus5 WoS5 Europe PMC3
2015	Gan, Z., Fitter, S., Vandyke, K., To, L., Zannettino, A., & Martin, S. (2015). The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. European Journal of Haematology, 94(4), 343-354. DOI Scopus15 WoS14 Europe PMC9
2014	Noll, J., Hewett, D., Williams, S., Vandyke, K., Kok, C., To, L., & Zannettino, A. (2014). SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia, 16(7), 572-585. DOI Scopus15 WoS15 Europe PMC15
2014	Noll, J., Williams, S., Tong, C., Wang, H., Quach, J., Purton, L., . . . Zannettino, A. (2014). Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica, 99(1), 163-171. DOI Scopus51 WoS44 Europe PMC41
2014	Richardson, J., Psaltis, P., Frost, L., Paton, S., Carbone, A., Bertaso, A., . . . Worthley, S. (2014). Incremental benefits of repeated mesenchymal stromal cell administration compared with solitary intervention after myocardial infarction. Cytotherapy, 16(4), 460-470. DOI Scopus10 WoS10 Europe PMC10
2014	Whittaker, J., Choudhury, N., Dutta, N., & Zannettino, A. (2014). Facile and rapid ruthenium mediated photo-crosslinking of Bombyx mori silk fibroin. Journal of Materials Chemistry B, 2(37), 6259-6270. DOI Scopus15 WoS14
2014	Ahmed, F., Dutta, N., Zannettino, A., Vandyke, K., & Choudhury, N. (2014). Engineering interaction between bone marrow derived endothelial cells and electrospun surfaces for artificial vascular graft applications. Biomacromolecules, 15(4), 1276-1287. DOI Scopus8 WoS8 Europe PMC4
2014	Ahmed, F., Choudhury, N., Dutta, N., Brito E Abreu, S., Zannettino, A., & Duncan, E. (2014). Interaction of platelets with poly(vinylidene fluoride-co- hexafluoropropylene) electrospun surfaces. Biomacromolecules, 15(3), 744-755. DOI Scopus8 WoS8 Europe PMC5
2014	Zinonos, I., Luo, K., Labrinidis, A., Liapis, V., Hay, S., Panagopoulos, V., . . . Evdokiou, A. (2014). Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer. International Journal of Oncology, 45(2), 532-540. DOI Scopus14 WoS13 Europe PMC10
2014	Ahmed, F., Roy Choudhury, N., Dutta, N., Zou, L., & Zannettino, A. (2014). Fabrication and characterisation of an electrospun tubular 3D scaffold platform of poly(vinylidene fluoride-co-hexafluoropropylene) for small-diameter blood vessel application. Journal of Biomaterials Science, Polymer Edition, 25(18), 2023-2041. DOI Scopus4 WoS3 Europe PMC1
2014	Hemming, S., Cakouros, D., Isenmann, S., Cooper, L., Menicanin, D., Zannettino, A., & Gronthos, S. (2014). EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification. Stem cells, 32(3), 802-815. DOI Scopus89 WoS83 Europe PMC76
2014	Frith, J., Menzies, D., Cameron, A., Ghosh, P., Whitehead, D., Gronthos, S., . . . Cooper-White, J. (2014). Effects of bound versus soluble pentosan polysulphate in PEG/HA-based hydrogels tailored for intervertebral disc regeneration. Biomaterials, 35(4), 1150-1162. DOI Scopus25 WoS26 Europe PMC17
2014	Zinonos, I., Labrinidis, A., Liapis, V., Hay, S., Panagopoulos, V., Denichilo, M., . . . Evdokiou, A. (2014). Doxorubicin overcomes resistance to drozitumab by antagonizing inhibitor of apoptosis proteins (IAPS). Anticancer Research, 34(12), 7007-7020. Scopus2 WoS2 Europe PMC2
2013	Ahmed, F., Choudhury, N., Dutta, N., Zannettino, A., & Knott, R. (2013). Near superhydrophobic fibrous scaffold for endothelialization: Fabrication, characterization and cellular activities. Biomacromolecules, 14(11), 3850-3860. DOI Scopus14 WoS15 Europe PMC5
2013	Richardson, J., Bertaso, A., Frost, L., Psaltis, P., Carbone, A., Koschade, B., . . . Worthley, S. (2013). Cardiac magnetic resonance, transthoracic and transoesophageal echocardiography: a comparison of invivo assessment of ventricular function in rats. Laboratory Animals, 47(4), 291-300. DOI Scopus6 WoS6 Europe PMC4
2013	Frith, J., Cameron, A., Menzies, D., Ghosh, P., Whitehead, D., Gronthos, S., . . . Cooper-White, J. (2013). An injectable hydrogel incorporating mesenchymal precursor cells and pentosan polysulphate for intervertebral disc regeneration. Biomaterials, 34(37), 9430-9440. DOI Scopus61 WoS55 Europe PMC34
2013	Goldschlager, T., Oehme, D., Ghosh, P., Zannettino, A., Rosenfeld, J., & Jenkin, G. (2013). Current and future applications for stem cell therapies in spine surgery. Current Stem Cell Research & Therapy, 8(5), 381-393. DOI Scopus13 WoS9 Europe PMC6
2013	Richardson, J., Bertaso, A., Psaltis, P., Frost, L., Carbone, A., Paton, S., . . . Worthley, S. (2013). Impact of timing and dose of mesenchymal stromal cell therapy in a preclinical model of acute myocardial infarction. Journal of Cardiac Failure, 19(5), 342-353. DOI Scopus31 WoS31 Europe PMC20
2013	Richardson, J., Nelson, A., Zannettino, A., Gronthos, S., Worthley, S., & Psaltis, P. (2013). Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step. Stem Cell Reviews, 9(3), 281-302. DOI Scopus19 WoS18 Europe PMC15
2013	Vandyke, K., Chow, A., Williams, S., To, L., & Zannettino, A. (2013). Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. British Journal of Haematology, 161(4), 499-507. DOI Scopus9 WoS13 Europe PMC9
2013	Thomas, D., Powell, J., Green, B., Barry, E., Ma, Y., Woodcock, J., . . . Guthridge, M. (2013). Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. PLoS Biology, 11(3), 1-14. DOI Scopus14 WoS12 Europe PMC13
2013	Arthur, A., Panagopoulos, R., Cooper, L., Menicanin, D., Parkinson, I., Codrington, J., . . . Gronthos, S. (2013). EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. Journal of Bone and Mineral Research, 28(4), 926-935. DOI Scopus26 WoS22 Europe PMC19
2013	Vandyke, K., Fitter, S., Drew, J., Fukumoto, S., Schultz, C., Sims, N., . . . Zannettino, A. (2013). Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effects. Journal of Clinical Endocrinology and Metabolism, 98(1), 67-76. DOI Scopus12 WoS11 Europe PMC10
2012	Castrechini, N., Murthi, P., Qin, S., Kusuma, G., Wilton, L., Abumaree, M., . . . Kalionis, B. (2012). Decidua parietalis-derived mesenchymal stromal cells reside in a vascular niche within the choriodecidua. Reproductive Sciences, 19(12), 1302-1314. DOI Scopus24 WoS21 Europe PMC19
2012	Noll, J., Williams, S., Purton, L., & Zannettino, A. (2012). Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?. Blood Cancer Journal, 2(9), 1-10. DOI Scopus30 WoS21 Europe PMC19
2012	Fitter, S., Vandyke, K., Gronthos, S., & Zannettino, A. (2012). Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. Journal of Molecular Endocrinology, 48(3), 229-240. DOI Scopus36 WoS33 Europe PMC31
2012	Ghosh, P., Moore, R., Vernon-Roberts, B., Goldschlager, T., Pascoe, D., Zannettino, A., . . . Itescu, S. (2012). Immunoselected STRO-3⁺ mesenchymal precursor cells and restoration of the extracellular matrix of degenerate intervertebral discs: Laboratory investigation. Journal of Neurosurgery: Spine, 16(5), 479-488. DOI Scopus51 WoS46 Europe PMC34
2012	Pyragius, C., Georgiou, K., Foster, B., Zannettino, A., & Xian, C. (2012). Microarray expression analysis of genes and pathways involved in growth plate cartilage injury responses and bony repair. Bone, 50(5), 1081-1091. DOI Scopus31 WoS28 Europe PMC22
2012	Weber, B., Emmert, M., Behr, L., Schoenauer, R., Brokopp, C., Drogemuller, C., . . . Hoerstrup, S. (2012). Prenatally engineered autologous amniotic fluid stem cell-based heart valves in the fetal circulation. Biomaterials, 33(16), 4031-4043. DOI Scopus46 WoS39 Europe PMC36
2012	Cakouros, D., Isenmann, S., Cooper, L., Zannettino, A., Anderson, P., Glackin, C., & Gronthos, S. (2012). Twist-1 Induces Ezh2 Recruitment Regulating Histone Methylation along the Ink4A/Arf Locus in Mesenchymal Stem Cells. Molecular and Cellular Biology, 32(8), 1433-1441. DOI Scopus58 WoS58 Europe PMC50
2012	Crotti, T., Dharmapatni, A., Alias, E., Zannettino, A., Smith, M., & Haynes, D. (2012). The immunoreceptor tyrosine-based activation motif (ITAM)-related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. Arthritis Research & Therapy, 14(6), 1-13. DOI Scopus27 WoS23 Europe PMC22
2011	Andersen, D., Kortesidis, A., Zannettino, A., Kratchmarova, I., Chen, L., Jensen, O., . . . Kassem, M. (2011). Development of novel monoclonal antibodies that define differentiation stages of human stromal (mesenchymal) stem cells. Molecules and Cells, 32(2), 133-142. DOI Scopus8 WoS8 Europe PMC6
2011	Vandyke, K., Fitter, S., & Zannettino, A. (2011). The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer Journal, 1(2), E2. DOI Scopus13 WoS12 Europe PMC7
2011	Freeman, L., Lam, A., Petcu, E., Smith, R., Salajegheh, A., Diamond, P., . . . Vuckovic, S. (2011). Myeloma-induced alloreactive T cells arising in myeloma-infiltrated bones include double-positive CD8⁺CD4⁺ T cells: evidence from myeloma-bearing mouse model. Journal of Immunology, 187(8), 3987-3996. DOI Scopus8 WoS8 Europe PMC6
2011	Martin, S., Diamond, P., Gronthos, S., Peet, D., & Zannettino, A. (2011). The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia, 25(10), 1533-1542. DOI Scopus72 WoS67 Europe PMC62
2011	Nath, S., Nicholson, I., Tapp, H., Zola, H., Zannettino, A., & Revesz, T. (2011). Reticulin fibres anchor leukaemic blasts in the marrow of patients with acute lymphoblastic leukaemia. Medical Hypotheses, 77(3), 333-335. DOI Scopus4 WoS5 Europe PMC4
2011	Dharmapatni, A., Smith, M., Crotti, T., Holding, C., Vincent, C., Weedon, H., . . . Haynes, D. (2011). TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Research & Therapy, 13(2), R51-1-R51-10. DOI Scopus27 WoS24 Europe PMC19
2011	Field, J., Mc Gee, M., Stanley, R., Ruthenbeck, G., Papadimitrakis, T., Zannettino, A., . . . Itescu, S. (2011). The efficacy of allogeneic mesenchymal precursor cells for the repair of an ovine tibial segmental defect. Veterinary and Comparative Orthopaedics and Traumatology, 24(2), 113-121. DOI Scopus25 WoS27 Europe PMC18
2011	Arthur, A., Zannettino, A., Panagopoulos, R., Koblar, S., Sims, N., Stylianou, C., . . . Gronthos, S. (2011). EphB/ephrin-B interactions mediate human MSC attachment, migration and osteochondral differentiation. Bone, 48(3), 533-542. DOI Scopus54 WoS50 Europe PMC48
2011	See, F., Seki, T., Psaltis, P., Sondermeijer, H., Gronthos, S., Zannettino, A., . . . Itescu, S. (2011). Therapeutic Effects of Human STRO-3-Selected Mesenchymal Precursor Cells and their Soluble Factors in Experimental Myocardial Ischemia. Journal of Cellular and Molecular Medicine, 15(10), 2117-2129. DOI Scopus31 WoS31 Europe PMC26
2011	Engler, J., Zannettino, A., Bailey, C., Rasko, J., Hughes, T., & White, D. (2011). OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica: the haematology journal, 96(2), 1-33. DOI Scopus11 WoS10 Europe PMC10
2011	Goldschlager, T., Ghosh, P., Zannettino, A., Williamson, M., Rosenfeld, J., Itescu, S., & Jenkin, G. (2011). A Comparison of mesenchymal precursor cells and amnion epithelial cells for enhancing cervical interbody fusion in an ovine model. Neurosurgery, 68(4), 1025-1034. DOI Scopus18 WoS15 Europe PMC16
2011	Zinonos, I., Labrinidis, A., Lee, M., Liapis, V., Hay, S., Ponomarev, V., . . . Evdokiou, A. (2011). Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. Journal of Bone and Mineral Research, 26(3), 630-643. DOI Scopus14 WoS14 Europe PMC11
2011	Psaltis, P., Carbone, A., Leong, D., Lau, D., Nelson, A., Kuchel, T., . . . Worthley, S. (2011). Assessment of myocardial fibrosis by endoventricular electromechanical mapping in experimental nonischemic cardiomyopathy. International Journal of Cardiovascular Imaging, 27(1), 25-37. DOI Scopus21 WoS22 Europe PMC20
2011	Field, J., McGee, M., Stanley, R., Ruthenbeck, G., Papadimitrakis, T., Zannettino, A., . . . Itescu, S. (2011). The efficacy of allogeneic mesenchymal precursor cells for the repair of an ovine tibial segmental defect. Veterinary and Comparative Orthopaedics and Traumatology, 24(3), 256. DOI Scopus2
2010	Goldschlager, T., Jenkin, G., Ghosh, P., Zannettino, A., & Rosenfeld, J. V. (2010). Potential applications for using stem cells in spine surgery. Current Stem Cell Research and Therapy, 5(4), 345-355. DOI Scopus11 WoS7 Europe PMC6
2010	Goldschlager, T., Ghosh, P., Zannettino, A., Gronthos, S., Rosenfeld, J., Itescu, S., & Jenkin, G. (2010). Cervical motion preservation using mesenchymal progenitor cells and pentosan polysulfate, a novel chondrogenic agent: preliminary study in an ovine model. Neurosurgical Focus, 28(6), E4-1-E4-8. DOI Scopus19 WoS16 Europe PMC11
2010	Ghosh, P., Wu, J., Shimmon, S., Zannettino, A., Gronthos, S., & Itescu, S. (2010). Pentosan polysulfate promotes proliferation and chondrogenic differentiation of adult human bone marrow-derived mesenchymal precursor cells. Arthritis Research & Therapy, 12(1), R28-1-R28-17. DOI Scopus28 WoS25 Europe PMC18
2010	Martin, S., Diamond, P., Williams, S., To, L., Peet, D., Fujii, N., . . . Zannettino, A. (2010). Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica, 95(5), 776-784. DOI Scopus58 WoS51 Europe PMC39
2010	Psaltis, P., Paton, S., See, F., Arthur, A., Martin, S., Itescu, S., . . . Zannettino, A. (2010). Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. Journal of Cellular Physiology, 223(2), 530-540. DOI Scopus93 WoS90 Europe PMC74
2010	Engler, J., Frede, A., Saunders, V., Zannettino, A., Hughes, T., & White, D. (2010). Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity. Leukemia, 24(4), 765-770. DOI Scopus47 WoS44 Europe PMC33
2010	Vandyke, K., Fitter, S., Dewar, A., Hughes, T., & Zannettino, A. (2010). Dysregulation of bone remodeling by imatinib mesylate. Blood, 115(4), 766-774. DOI Scopus87 WoS77 Europe PMC61
2010	Psaltis, P., Zannettino, A., Gronthos, S., & Worthley, S. (2010). Intramyocardial navigation and mapping for stem cell delivery. Journal of Cardiovascular Translational Research, 3(2 Sp Iss), 135-146. DOI Scopus19 WoS18 Europe PMC12
2010	Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Schultz, C., Sims, N., & Zannettino, A. (2010). The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. Journal of Bone and Mineral Research, 25(8), 1759-1770. DOI Scopus57 WoS52 Europe PMC42
2010	Zannettino, A., Paton, S., Itescu, S., & Gronthos, S. (2010). Comparative assessment of the osteoconductive properties of different biomaterials in vivo seeded with human or ovine mesenchymal stem/stromal cells. Tissue Engineering. Part A. Tissue Engineering, 16(12), 3579-3587. DOI Scopus26 WoS26 Europe PMC19
2010	McCarty, R., Xian, C., Gronthos, S., Zannettino, A., & Foster, B. (2010). Application of autologous bone marrow derived mesenchymal stem cells to an ovine model of growth plate cartilage injury. The Open Orthopaedics Journal, 4(1), 220-226. DOI Scopus39 Europe PMC24
2010	Engler, J., Frede, A., Saunders, V., Zannettino, A., White, D., & Hughes, T. (2010). The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells. Blood, 116(15), 2776-2778. DOI Scopus17 WoS16 Europe PMC11
2010	Martin, S., Fitter, S., Bong, L., Drew, J., Gronthos, S., Shepherd, P., & Zannettino, A. (2010). NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. Journal of Bone and Mineral Research, 25(10), 2126-2137. DOI Scopus44 WoS41 Europe PMC38
2010	Psaltis, P., Carbone, A., Nelson, A., Lau, D., Jantzen, T., Manavis, J., . . . Worthley, S. (2010). Reparative effects of allogeneic mesenchymal precursor cells delivered transendocardially in experimental nonischemic cardiomyopathy. JACC: Cardiovascular Interventions, 3(9), 974-983. DOI Scopus38 WoS38 Europe PMC30
2010	Menicanin, D., Bartold, P., Zannettino, A., & Gronthos, S. (2010). Identification of a common gene expression signature associated with immature clonal mesenchymal cell populations derived from bone marrow and dental tissues. Stem Cells and Development, 19(10), 1501-1510. DOI Scopus45 WoS39 Europe PMC33
2010	Fitter, S., Vandyke, K., Schultz, C., White, D., Hughes, T., & Zannettino, A. (2010). Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?. Journal of Clinical Endocrinology and Metabolism, 95(8), 3763-3767. DOI Scopus31 WoS29 Europe PMC26
2010	Winkler, I., Barbier, V., Wadley, R., Zannettino, A., Williams, S., & Levesque, J. (2010). Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood, 116(3), 375-385. DOI Scopus154 WoS141 Europe PMC124
2010	Williams, S., Martin, S., Vincent, C., Gronthos, S., Zheng, T., Atkins, G., & Zannettino, A. (2010). Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients. British Journal of Haematology, 150(3), 373-376. DOI Scopus5 WoS5 Europe PMC2
2010	Castrechini, N., Murthi, P., Gude, N., Erwich, J., Gronthos, S., Zannettino, A., . . . Kalionis, B. (2010). Mesenchymal stem cells in human placental chorionic villi reside in a vascular Niche. Placenta, 31(3), 203-212. DOI Scopus87 WoS77 Europe PMC61
2009	Isenmann, S., Arthur, A., Zannettino, A., Turner, J., Shi, S., Glackin, C., & Gronthos, S. (2009). TWIST family of basic helix-loop-helix transcription factors mediate human mesenchymal stem cell growth and commitment. Stem Cells, 27(10), 2457-2468. DOI Scopus122 WoS120 Europe PMC103
2009	Gronthos, S., McCarty, R., Mrozik, K., Fitter, S., Paton, S., Menicanin, D., . . . Zannettino, A. (2009). Heat shock protein-90 beta is expressed at the surface of multipotential mesenchymal precursor cells: Generation of a novel monoclonal antibody, STRO-4, with specificity for mesenchymal precursor cells from human and ovine tissues. Stem Cells and Development, 18(9), 1253-1261. DOI Scopus57 WoS52 Europe PMC37
2009	Zinonos, I., Labrinidis, A., Lee, M., Liapis, V., Hay, S., Ponomarev, V., . . . Evdokiou, A. (2009). Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Molecular Cancer Therapeutics, 8(10), 2969-2980. DOI Scopus35 WoS35 Europe PMC26
2009	Arthur, A., Shi, S., Zannettino, A., Fujii, N., Gronthos, S., & Koblar, S. (2009). Implanted adult human dental pulp stem cells induce endogenous axon guidance. Stem Cells, 27(9), 2229-2237. DOI Scopus95 WoS92 Europe PMC75
2009	Paquet- Fifield, S., Schluter, H., Li, A., Aitken, T., Gangatirkar, P., Blashki, D., . . . Kaur, P. (2009). A role for pericytes as microenvironmental regulators of human skin tissue regeneration. Journal of Clinical Investigation, 119(9), 2795-2806. DOI Scopus118 WoS107 Europe PMC82
2009	Vandyke, K., Dewar, A., Menicanin, D., To, L., Hughes, T., Zannettino, A., & Fitter, S. (2009). Imatinib mesylate causes growth plate closure in vivo. Leukemia, 23(11), 2155-2159. DOI Scopus30 WoS29 Europe PMC28
2009	Diamond, P., Labrinidis, A., Martin, S., Farrugia, A., Gronthos, S., To, L., . . . Zannettino, A. (2009). Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. Journal of Bone and Mineral Research, 24(7), 1150-1161. DOI Scopus44 WoS46 Europe PMC33
2009	Dickinson, M., Prince, H., Kirsa, S., Zannettino, A., Gibbs, S., Mileshkin, L., . . . Joshua, D. (2009). Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Internal Medicine Journal, 39(5), 304-316. DOI Scopus32 WoS30 Europe PMC19
2009	Vandyke, K., Dewar, A., Farrugia, A., Fitter, S., To, B., Hughes, T., & Zannettino, A. (2009). Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia, 23(5), 994-997. DOI Scopus42 WoS40 Europe PMC32
2009	Menicanin, D., Bartold, P., Zannettino, A., & Gronthos, S. (2009). Genomic Profiling of Mesenchymal Stem Cells. Stem Cell Reviews, 5(1), 36-50. DOI Scopus59 WoS52 Europe PMC37
2009	Chung, R., Foster, B., Zannettino, A., & Xian, C. (2009). Potential roles of growth factor PDGF-BB in the bony repair of injured growth plate. Bone, 44(5), 878-885. DOI Scopus45 WoS42 Europe PMC27
2009	Mc Carty, R., Gronthos, S., Zannettino, A., Foster, B., & Xian, C. (2009). Characterisation and Developmental Potential of Ovine Bone Marrow Derived Mesenchymal Stem Cells. Journal of Cellular Physiology, 219(2), 324-333. DOI Scopus103 WoS89 Europe PMC68
2009	Labrinidis, A., Diamond, P., Martin, S., Hay, S., Liapis, V., Zinonos, I., . . . Evdokiou, A. (2009). Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clinical Cancer Research, 15(6), 1998-2009. DOI Scopus30 WoS28 Europe PMC23
2009	Arthur, A., Zannettino, A., & Gronthos, S. (2009). The Therapeutic Applications of Multipotential Mesenchymal/Stromal Stem Cells in Skeletal Tissue Repair. Journal of Cellular Physiology, 218(2), 237-245. DOI Scopus241 WoS212 Europe PMC148
2009	Psaltis, P., Carbone, A., Lau, D., Jantzen, T., Williams, K., Sanders, P., . . . Worthley, S. (2009). Purkinje fiber injury and electrical remodeling in non-ischemic cardiomyopathy: Implications for sudden cardiac death. EUROPEAN HEART JOURNAL, 30, 558.
2009	Psaltis, P., See, F., Paton, S., Martens, T., Itescu, S., Worthley, S., . . . Zannettino, A. (2009). STRO-1 immunoselection enhances the biological properties and cardiovascular paracrine effects of bone marrow mesenchymal stromal cells. EUROPEAN HEART JOURNAL, 30, 501.
2009	Zinonos, I., Labrinidis, A., Liapis, V., Hay, S., Lee, M., Ponomarev, V., . . . Evdokiou, A. (2009). Apomab, a fully human agonistic DR5 monoclonal antibody inhibits tumor growth and osteolysis in murine models of breast cancer development and progression. CANCER RESEARCH, 69, 2 pages.
2009	Zinonos, I., Labrinidis, A., Liapis, V., Hay, S., Lee, M., Ponomarev, V., . . . Evdokiou, A. (2009). Apomab, a fully human agonistic DR5 monoclonal antibody inhibits tumor growth and osteolysis in murine models of breast cancer development and progression. CANCER RESEARCH, 69, 2 pages.
2008	Psaltis, P., Gronthos, S., Worthley, S., & Zannettino, A. (2008). Cellular therapy for cardiovascular disease Part 1 - Preclinical insights. Clinical Medicine Insights : Cardiology, 2, 125-138.
2008	Psaltis, P., Gronthos, S., Worthley, S., & Zannettino, A. (2008). Cellular therapy for cardiovascular disease Part 2 - Delivery of cells and clinical experience. Clinical Medicine Insights : Cardiology, 2, 139-151.
2008	Zannettino, A., Paton, S., Kortesidis, A., Khor, F., Itescu, S., & Gronthos, S. (2008). Human mulipotential mesenchymal/stromal stem cells are derived from a discrete subpopulation of STRO-1bright/CD34-/CD45-/glycophorin-A-bone marrow cells. Haematologica, 92(12), 1707-1708. DOI Scopus66 WoS58 Europe PMC43
2008	Psaltis, P., Carbone, A., Nelson, A., Lau, D., Manavis, J., Finnie, J., . . . Worthley, S. (2008). An ovine model of toxic, nonischemic cardiomyopathy-assessment by cardiac magnetic resonance imaging. Journal of Cardiac Failure, 14(9), 785-795. DOI Scopus19 WoS15 Europe PMC10
2008	Labrinidis, A., Liapis, V., Thai, L., Atkins, G., Vincent, C., Hay, S., . . . Evdokiou, A. (2008). Does Apo2LTRAIL play any physiologic role in osteoclastogenesis?. Blood, 111(11), 5411-5412. DOI Scopus15 WoS13 Europe PMC7
2008	Psaltis, P., Zannettino, A., Worthley, S., & Gronthos, S. (2008). Concise review: Mesenchymal stromal cells: Potential for cardiovascular repair. Stem Cells, 26(9), 2201-2210. DOI Scopus272 WoS238 Europe PMC190
2008	Zannettino, A., Psaltis, P., & Gronthos, S. (2008). Home is where the heart is: Via the FROUNT. Cell Stem Cell, 2(6), 513-514. DOI
2008	Fitter, S., Dewar, A., Kostakis, P., To, L., Hughes, T., Roberts, M., . . . Zannettino, A. (2008). Long-term imatinib therapy promotes bone formation in CML patients. Blood, 111(5), 2538-2547. DOI Scopus120 WoS114 Europe PMC89
2008	Zannettino, A., Paton, S., Arthur, A., Khor, F., Itescu, S., Gimble, J., & Gronthos, S. (2008). Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivo. Journal of Cellular Physiology, 214(2), 413-421. DOI Scopus393 WoS348 Europe PMC274
2007	Gronthos, S., Fitter, S., Diamond, P., Simmons, P., Itescu, S., & Zannettino, A. (2007). A novel monoclonal antibody (STRO-3) identifies an isoform of tissue nonspecific alkaline phosphatase expressed by multipotent bone marrow stromal stem cells. Stem Cells and Development, 16(6), 953-963. DOI Scopus85 WoS81 Europe PMC67
2007	White, D., Saunders, V., Dang, P., Engler, J., Venables, A., Zrim, S., . . . Hughes, T. (2007). Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood, 110(12), 4064-4072. DOI Scopus240 WoS219 Europe PMC173
2007	Isenmann, S., Cakouros, D., Zannettino, A., Shi, S., & Gronthos, S. (2007). hTERT Transcription is repressed by Cbfa1 in human mesenchymal stem cell populations. Journal of Bone and Mineral Research, 22(6), 897-906. DOI Scopus21 WoS20 Europe PMC15
2007	Atkins, G., Anderson, P., Findlay, D., Welldon, K., Vincent, C., Zannettino, A., . . . Morris, H. (2007). Metabolism of vitamin D₃ in human osteoblasts: Evidence for autocrine and paracrine activities of 1α,25-dihydroxyvitamin D₃. Bone, 40(6), 1517-1528. DOI Scopus165 WoS153 Europe PMC111
2007	Gronthos, S., & Zannettino, A. (2007). The role of the chemokine CXCL12 in osteoclastogenesis. Trends in Endocrinology and Metabolism, 18(3), 108-113. DOI Scopus33 WoS27 Europe PMC20
2007	Macsai, C., Scherer, M., Zannettino, A., Foster, B., & Xian, C. (2007). Expression of Wnt signaling molecules at the injured growth plate cartilage in young rats. CALCIFIED TISSUE INTERNATIONAL, 80, S54. WoS2
2006	Evans, A., Jackson, D., Wall, D., Prince, H. M., Gronthos, S., Zannettino, A., . . . Itescu, S. (2006). Ex vivo expansion of immuno-selected autologous mesenchymal precursor cells (MPC) for use in the treatment of chronic myocardial ischaemia.. CYTOTHERAPY, 8, 1 page.
2006	Potential of bone marrow stromal stem cells to repair bone defects and fractures (2006). Journal of Stem Cells, 1(1), 35-45. Scopus3
2006	Tsangari, H., Findlay, D., Zannettino, A., Pan, B., Kuliwaba, J., & Fazzalari, N. (2006). Evidence for reduced bone formation surface relative to bone resorption surface in female femoral fragility fracture patients. Bone, 39(6), 1226-1235. DOI Scopus17 WoS16 Europe PMC11
2006	Martin, S., Dewar, A., Farrugia, A., Horvath, N., Gronthos, S., To, L., & Zannettino, A. (2006). Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1α in patients with multiple myeloma. Clinical Cancer Research, 12(23), 6973-6977. DOI Scopus22 WoS21 Europe PMC15
2006	Atkins, G., Kostakis, P., Vincent, C., Farrugia, A., Houchins, J., Findlay, D., . . . Zannettino, A. (2006). RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. Journal of Bone and Mineral Research, 21(9), 1339-1349. DOI Scopus73 WoS72 Europe PMC55
2006	White, D., Saunders, V., Dang, P., Engler, J., Zannettino, A., Cambareri, A., . . . Hughes, T. (2006). OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood, 108(2), 697-704. DOI Scopus338 WoS292 Europe PMC224
2006	Dewar, A., Farrugia, A., Condina, M., To, L., Hughes, T., Vernon-Roberts, B., & Zannettino, A. (2006). Imatinib as a potential antiresorptive therapy for bone disease. Blood, 107(11), 4334-4337. DOI Scopus62 WoS59 Europe PMC48
2006	Martens, T., See, F., Shuster, M., Sondermeijer, H., Hefti, M., Zannettino, A., . . . Itescu, S. (2006). Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. Nature Clinical Practice Cardiovascular Medicine, 3(Suppl 1), 18-22. DOI Scopus77 Europe PMC48
2005	Dewar, A., Zannettino, A., Hughes, T., & Lyons, A. (2005). Inhibition of c-fms by imatinib - Expanding the spectrum of treatment. Cell Cycle, 4(7), 851-853. DOI Scopus43 WoS41 Europe PMC33
2005	Zannettino, A., Holding, C., Diamond, P., Atkins, G., Kostakis, P., Farrugia, A., . . . Haynes, D. (2005). Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. Journal of Cellular Physiology, 204(2), 714-723. DOI Scopus111 WoS111 Europe PMC83
2005	Dewar, A., Cambareri, A., Zannettino, A., Boog, B., Doherty, K., Hughes, T., & Lyons, A. (2005). Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood, 105(8), 3127-3132. DOI Scopus233 WoS216 Europe PMC153
2005	Atkins, G., Kostakis, P., Welldon, K., Vincent, C., Findlay, D., & Zannettino, A. (2005). Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. Journal of Cellular Physiology, 203(3), 573-582. DOI Scopus26 WoS27 Europe PMC19
2005	Kortesidis, A., Zannettino, A., Isenmann, S., Shi, S., Lapidot, T., & Gronthos, S. (2005). Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood, 105(10), 3793-3801. DOI Scopus283 WoS270 Europe PMC223
2005	Zannettino, A., Farrugia, A., Kortesidis, A., Manavis, J., To, L., Martin, S., . . . Gronthos, S. (2005). Elevated serum levels of stromal-derived factor-1α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Research, 65(5), 1700-1709. DOI Scopus147 WoS138 Europe PMC102
2005	Martens, T., Schuster, M., Cheema, F., See, F., Topkara, V., Colman, D., . . . Itescu, S. (2005). Human mesenchymal progenitor cells induce arteriogenesis and cardiac regeneration following acute ischemia in irradiated nude rats. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 24(2), S98. DOI
2004	Farrugia, A., Atkins, G., & Bik To, L. (2004). Identification and Clinical Relevance of Receptor Activator of Nuclear Factor κB Ligand Expression of Myeloma Cells [2] (multiple letters). Cancer Research, 64(2), 773-775. Scopus1
2004	Zannettino, A., Pan, B., Farrugia, A., Atkins, G., & To, L. (2004). Identification and clinical relevance of receptor activator of nuclear factor kappa B ligand expression of myeloma cells - Reply. Cancer Research, 64(2), 774-775.
2004	Martin, S., To, L., Horvath, N., & Zannettino, A. (2004). Angiogenesis in multiple myeloma: Implications in myeloma therapy. Cancer Reviews: Asia-Pacific, 2(2), 119-129. DOI
2004	Findlay, D., Welldon, K., Atkins, G., Howie, D., Zannettino, A., & Bobyn, D. (2004). The proliferation and phenotypic expression of human osteoblasts on tantalum metal. Biomaterials, 25(12), 2215-2227. DOI Scopus138 WoS125 Europe PMC60
2004	Pan, B., To, L., Farrugia, A., Findlay, D., Green, J., Gronthos, S., . . . Zannettino, A. (2004). The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone, 34(1), 112-123. DOI Scopus76 WoS70 Europe PMC57
2004	Pan, B., Farrugia, A., To, L., Findlay, D., Green, J., Lynch, K., & Zannettino, A. (2004). The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). Journal of Bone and Mineral Research, 19(1), 147-154. DOI Scopus125 WoS113 Europe PMC91
2004	Hu, Y., Zhou, H., Myers, D., Quinn, J., Atkins, G., Ly, C., . . . Ng, K. (2004). Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts. Journal of Bone and Mineral Research, 19(1), 89-99. DOI Scopus34 WoS35 Europe PMC27
2003	Zannettino, A., Roubelakis, M., Welldon, K., Jackson, D., Simmons, P., Bendall, L., . . . Watt, S. (2003). Novel mesenchymal and haematopoietic cell isoforms of the SHP-2 docking receptor, PZR: identification, molecular cloning and effects on cell migration. Biochemical Journal, 370(2), 537-549. DOI Scopus18 WoS21 Europe PMC16
2003	Zannettino, A., Harrison, K., Joyner, C., Triffitt, J., & Simmons, P. (2003). Molecular cloning of the cell surface antigen identified by the osteoprogenitor-specific monoclonal antibody, HOP-26. Journal of Cellular Biochemistry, 89(1), 56-66. DOI Scopus33 WoS30 Europe PMC23
2003	Bendall, L., James, A., Zannettino, A., Simmons, P., Gottlieb, D., & Bradstock, K. (2003). A novel CD44 antibody identifies an epitope that is aberrantly expressed on acute lymphoblastic leukaemia cells. Immunology and Cell Biology, 81(4), 311-319. DOI Scopus4 WoS4 Europe PMC3
2003	Haynes, D., Barg, E., Crotti, T., Holding, C., Weedon, H., Atkins, G., . . . Smith, M. (2003). Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology, 42(1), 123-134. DOI Scopus115 WoS105 Europe PMC75
2003	Gronthos, S., Zannettino, A., Hay, S., Shi, S., Graves, S., Kortesidis, A., & Simmons, P. (2003). Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. Journal of Cell Science, 116(9), 1827-1835. DOI Scopus803 WoS704
2003	Atkins, G., Kostakis, P., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., . . . Zannettino, A. (2003). RANKL expression is related to the differentiation state of human osteoblasts. Journal of Bone and Mineral Research, 18(6), 1088-1098. DOI Scopus160 WoS155 Europe PMC116
2003	Farrugia, A., Atkins, G., To, L., Pan, B., Horvath, N., Kostakis, P., . . . Zannettino, A. (2003). Receptor activator of nuclear factor-kB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Research, 63(17), 5438-5445. Scopus180 WoS169 Europe PMC125
2003	Zhang, X., Fitzsimmons, R., Cleland, L., Ey, P., Zannettino, A., Farmer, E., . . . Mayrhofer, G. (2003). CD36/fatty acid translocase in rats: Distribution, isolation from hepatocytes, and comparison with the scavenger receptor SR-B1. Laboratory Investigation, 83(3), 317-332. DOI Scopus51 WoS46 Europe PMC32
2003	Pan, B., To, L., Farrugia, A., Kostakis, P., Atkins, G., Findlay, D., & Zannettino, A. (2003). Multiple myeloma-derived pro-inflammatory cytokines enhance osteoclastogenesis by increasing the number of RANKL-expressing STRO-1 positive osteoprogenitor cells. Blood, 102(11), 5207.
2003	Gronthos, S., Zannettino, A. C., Hay, S. J., Shi, S., Graves, S. E., Kortesidis, A., & Simmons, P. J. (2003). Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow.. Journal of cell science, 116(Pt 9), 1827-1835. DOI Europe PMC549
2002	Zreiqat, H., Howlett, C., Zannettino, A., Evans, P., Schulze-Tanzil, G., Knabe, C., & Shakibaei, M. (2002). Mechanisms of magnesium-stimulated adhesion of osteoblastic cells to commonly used orthopaedic implants. Journal of Biomedical Materials Research, 62(2), 175-184. DOI Scopus477 WoS432 Europe PMC187
2002	Atkins, G., Bouralexis, S., Evdokiou, A., Hay, S., Labrinidis, A., Zannettino, A., . . . Findlay, D. (2002). Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone, 31(4), 448-456. DOI Scopus55 WoS57 Europe PMC36
2002	Atkins, G., Haynes, D., Zannettino, A., Capone, M., Crotti, T., & Findlay, D. (2002). Haemopoietic cells influence stromal cell gene expression during human osteoclast development. Journal of Bone and Joint Surgery - British Volume, 84B(Suppl.3), 235.
2001	Atkins, G., Bouralexis, S., Haynes, D., Graves, S., Geary, S., Evdokiou, A., . . . Findlay, D. (2001). Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone, 28(4), 370-377. DOI Scopus72 WoS69 Europe PMC51
2001	Lee-Prudhoe, J., Jorgensen, B., Ihrke, G., Doyonnas, R., Zannettino, A., Buckle, V., . . . Watt, S. (2001). Relationship between novel isoforms, functionally important domains, and subcellular distribution of CD164/endolyn. Journal of Biological Chemistry, 276(3), 2139-2152. DOI Scopus31 WoS32 Europe PMC24
2001	Simmons, P., Zannettino, A., Harrison-Findik, D., Swart, B., Tomlinson, S., Hill, B., & Javni, J. (2001). A novel epitope of CD59 expressed by primitive human hematopoietic progenitors. Experimental Hematology, 29(12), 1474-1483. DOI WoS1 Europe PMC1
2001	Zannettino, A. (2001). CD164. Journal of Biological Regulators and Homeostatic Agents, 15(4), 394-396. Scopus2 WoS2 Europe PMC2
2001	Stewart, K., Gronthos, S., Bord, S., Zannettino, A., Simmons, P., & Beresford, J. (2001). Further characterisation and molecular cloning of the antibody H8G. JOURNAL OF BONE AND MINERAL RESEARCH, 16(6), 1183.
2000	Bendall, L., James, A., Zannettino, A., Simmons, P., Gottlieb, D., & Bradstock, K. (2000). A novel CD44 antibody provides evidence for coexpression of CD44 molecules in different activation states on hematopoietic cells.. BLOOD, 96(11), 687A.
2000	Doyonnas, R., Chan, J., Butler, L., Rappold, I., Lee-Prudhoe, J., Zannettino, A., . . . Watt, S. (2000). CD164 monoclonal antibodies that block hemopoietic progenitor cell adhesion and proliferation interact with the first mucin domain of the CD164 receptor. Journal of Immunology, 165(2), 840-851. DOI Scopus36 WoS35 Europe PMC29
2000	Chan, J., Levesque, J., Peault, B., & Roxanis, I. (2000). Functionally defined CD164 epitopes are expressed on CD34<sup>+</sup>cells throughout ontogeny but display distinct distribution patterns in adult hematopoietic and nonhematopoietic tissues. Blood, 95(10), 3113-3124. Scopus60 WoS59 Europe PMC42
2000	Identification and functional analysis of novel signaling receptors on primitive erythroid progenitor cells and bone marrow mesenchymal cells (2000). Blood, 96(11 PART I).
2000	Roubelakis, M., Zannettino, A., Harrison, K., Cheung, J., Henniker, A., Bendall, L., & Watt, S. (2000). Identification and functional analysis of novel signaling receptors on primitive erythroid progenitor cells and bone marrow mesenchymal cells.. BLOOD, 96(11), 84A.
1999	Levesque, J., Zannettino, A., Pudney, M., Kansas, G., Berndt, M., & Simmons, P. (1999). Adhesion to P-selectin suppresses growth of CD34+CD38-HPC and is mediated by PSGL-1/CD162. EXPERIMENTAL HEMATOLOGY, 27(7), 97.
1999	Zannettino, A., Graves, S., Gronthos, S., Hay, S., Smith, P., Harrison, K., & Simmons, P. (1999). The use of expanded populations of osteogenic precursors to reduce large bone defects.. JOURNAL OF BONE AND MINERAL RESEARCH, 14, S316.
1999	Simmons, P., Gronthos, S., Dibbens, L., Short, B., Zannettino, A., & Graves, S. (1999). The marrow stromal-haematopoietic interface. JOURNAL OF BONE AND MINERAL RESEARCH, 14(6), 1053.
1999	Levesque, J., Zannettino, A., Pudney, M., Niutta, S., Haylock, D., Snapp, K., . . . Simmons, P. (1999). PSGL-1-mediated adhesion of human hematopoietic progenitors to P-selectin results in supression of hematopoiesis. Immunity, 11(3), 369-378. DOI Scopus90 WoS85 Europe PMC47
1999	Gronthos, S., Zannettino, A., Graves, S., Ohta, S., Hay, S., & Simmons, P. (1999). Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. Journal of Bone and Mineral Research, 14(1), 47-56. DOI Scopus230 WoS215 Europe PMC163
1998	Ann Benton, M., & Simmons, P. (1998). The sialomucin CD164 (MGC-24v) is an adhesive glycoprotein expressed by human hematopoietic progenitors and bone marrow stromal cells that serves as a potent negative regulator of hematopoiesis. Blood, 92(8), 2613-2628. Scopus99 WoS91 Europe PMC61
1998	Harrison-Findik, D., Zannettino, A., Swart, B., Horejsi, V., & Simmons, P. (1998). Identification and characterisation of protein(s) responsible for novel binding of the anti-CD59 Mab HCC-1.. BLOOD, 92(10), 58B-59B.
1998	Horsfall, M., Zannettino, A., Nichol, J., Dyson, P., & Simmons, P. (1998). The monoclonal antibody ma6 identifies a cell surface antigen expressed on late bone marrow megakaryocytic progenitor cells. Experimental Hematology, 26(8), 740. Scopus1 WoS1
1998	Rappold, I., Chan, J., Lee-Prudhoe, J., Jones, T., Zannettino, A., Simmons, P., . . . Butler, L. (1998). Cd164, a novel sialomucin on cd34<sup>+</sup>and erythroid subsets, is located on human chromosome 6q21. Blood, 92(3), 849-866. Scopus54 WoS51 Europe PMC32
1998	Gottlieb, D., Simmons, P., & Bradstock, K. (1998). MUC18, a member of the immunoglobulin superfamily, is expressed on bone marrow fibroblasts and a subset of hematological malignancies. Leukemia, 12(3), 414-421. DOI Scopus70 WoS64 Europe PMC52
1998	Simmons, P., Zannettino, A., Levesque, J., Dibbens, L., Watt, S., Buhring, H., & Berndt, M. (1998). Mucin-like molecules as regulators of haemopoiesis. Experimental Hematology, 26(8), 703. Scopus1
1998	Watt, S., Chan, J., Lee-Prudhoe, J., Doyonnas, R., Tavian, M., Rappold, I., . . . Buehring, H. (1998). Differential glycosylation and splicing generates novel CD164 isoforms: A mechanism to control the functions of CD164 as an adhesion molecule and a potent negative regulator of hematopoiesis.. BLOOD, 92(10), 582A.
1998	Zannettino, A., Harrison, K., Nuitta, S., Henniker, A., Bendall, L., Bradstock, K., & Simmons, P. (1998). Molecular cloning of a novel immunoglobulin superfamily member expressed by hematopoietic progenitor and bone marrow stromal cells.. BLOOD, 92(10), 588A.
1997	Watt, S., Buhring, H., Chan, J., Rappold, I., LeePrudhoe, J., Benton, M., . . . Butler, L. (1997). The sialomicin CD164, a negative regulator of haemopoiesis, is expressed by CD341 and erythroid subsets and is located on chromosome 6q21.. EXPERIMENTAL HEMATOLOGY, 25(8), 53.
1997	Butler, L., Buhring, H., Zannettino, A., Rappold, I., Simmons, P., Niutta, S., & Watt, S. (1997). The functional epitopes of the novel adhesion molecule CD164 are differentially expressed by CD34(+) and erythroid subsets and within hematopoietic and nonhematopoietic tissues.. BLOOD, 90(10), 2139.
1997	Simmons, P., Sheer, D., & Butler, L. (1997). The sialomicin CD164, a negative regulator of haemopoiesis, is expressed by CD34<sup>+</sup>and erythroid subsets and is located on chromosome 6q21. Experimental Hematology, 25(8), 744.
1997	Hill, B., Neu, S., Knapp, W., Alitalo, R., Alitalo, K., Ullrich, A., . . . Bühring, H. (1997). Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood, 90(1), 111-125. Scopus109 WoS102 Europe PMC60
1997	Simmons, P., Levesque, J., & Zannettino, A. (1997). Adhesion molecules in haemopoiesis. Bailliere's Clinical Haematology, 10(3), 485-505. DOI Scopus86 WoS76 Europe PMC48
1997	Simmons, P., Gronthos, S., Zannettino, A., & Graves, S. (1997). Cell surface antigens expressed by bone marrow stromal cell precursors.. EXPERIMENTAL HEMATOLOGY, 25(8), 27.
1997	Cell surface antigens expressed by bone marrow stromal cell precursors (1997). Experimental Hematology, 25(8), 736.
1997	Zannettino, A., Aylett, G., Leavesley, D., Pietsch, T., Chang, D., Simmons, P., & Ashman, L. (1997). Specificity and functional effects of antibodies to human stem cell factor. Growth Factors, 14(1), 67-79. DOI Scopus4 WoS4 Europe PMC3
1996	Zannettino, A., Rayner, J., Ashman, L., Gonda, T., & Simmons, P. (1996). A powerful new technique for isolating genes encoding cell surface antigens using retroviral expression cloning. Journal of Immunology, 156(2), 611-620. Scopus41 WoS41 Europe PMC26
1996	Hoffman, R. (1996). High-level expression of a novel epitope of CD59 identifies a subset of CD34<sup>+</sup>bone marrow cells highly enriched for pluripotent stem cells. Experimental Hematology, 24(8), 936-943. Scopus20 WoS17 Europe PMC10
1996	Rappold, I., Ziegler, B., Kohler, I., Rosnet, O., Birnbaum, D., Simmons, P., . . . Buhring, H. (1996). Functional and phenotypic characterization of FLK2/FLT3 expressing cord blood and bone marrow cell subsets.. BLOOD, 88(10), 171.
1995	Zannettino, A., Buhring, H., Niutta, S., Ashman, L., Kanz, L., & Simmons, P. (1995). Identification and functional cloning of MGC-24, a mucin-like molecule expressed by haemopoietic progenitors and bone marrow stromal cells: A negative regulator of haemopoiesis. BLOOD, 86(10), 2350. WoS1
1995	Buhring, H., Zannettino, A., Scheding, S., Rappold, J., Simmons, P., & Kanz, L. (1995). Peanut agglutinin binding protein MGC-24 is a mucin preferentially expressed on erythroid cells and a subset of CD34+ bone marrow cells.. BLOOD, 86(10), 2624. WoS3
1995	Zannettino, A., Berndt, M., Nuitta, S., Butcher, C., Vadas, M., & Simmons, P. (1995). Primitive human haemopoietic progenitors adhere to P-selectin (CD62P). Blood, 85(12), 3466-3477. Scopus78 WoS83 Europe PMC44
1994	Simmons, P., Gronthos, S., Zannettino, A., Ohta, S., & Graves, S. (1994). Isolation, characterization and functional activity of human marrow stromal progenitors in hemopoiesis.. Progress in clinical and biological research, 389, 271-280. Scopus69 Europe PMC37
1994	SIMMONS, P., ZANNETTINO, A., GRONTHOS, S., & LEAVESLEY, D. (1994). Potential adhesion mechanisms for localisation of haemopoietic progenitors to bone marrow stroma. Leukemia and Lymphoma, 12(5-6), 353-363. DOI Scopus95 WoS97 Europe PMC35
1993	FITTER, S., BERNDT, M., ZANNETTINO, A., & ASHMAN, L. (1993). MOLECULAR-CLONING OF CDNA-ENCODING A NOVEL HUMAN PLATELET MEGAKARYOCYTE SURFACE-ANTIGEN. JOURNAL OF LEUKOCYTE BIOLOGY, 103.
1993	SIMMONS, P., ZANNETTINO, A., & LEAVESLEY, D. (1993). MOLECULAR DEFINITION OF THE ADHESIVE INTERACTIONS THAT REGULATE HEMATOPOIETIC STEM-CELLS. JOURNAL OF LEUKOCYTE BIOLOGY, 34.
1993	ZANNETTINO, A., RAYNER, J., ASHMAN, L., GONDA, T., & SIMMONS, P. (1993). USE OF A RETROVIRAL CDNA EXPRESSION LIBRARY TO CLONE GENES ENCODING NOVEL HUMAN STROMAL CELL ANTIGENS. JOURNAL OF LEUKOCYTE BIOLOGY, 103.

Book Chapters

Year	Citation
2013	Arthur, A. A., Zannettino, A., & Gronthos, S. (2013). The multipotential of Mesenchymal / Stromal Stem Cells in Skeletal Tissue Repair.. In R. Rajendram, V. R. Preedy, & V. B. Patel (Eds.), Stem Cells and Bone Tissue (pp. 82-102). DOI Scopus1
2011	Gronthos, S., & Zannettino, A. (2011). Methods for the purification and characterization of human adipose-derived stem cells.. In J. Gimble, & B. Bunnell (Eds.), Methods in Molecular Biology: Adipose-Derived Stem Cells - Methods and Protocols (Vol. 702, 1 ed., pp. 109-120). USA: Humana Press. DOI Scopus16 Europe PMC12
2008	Gronthos, S., & Zannettino, A. (2008). A method to isolate and purify human bone marrow stromal stem cells. In D. Prockop, D. Phinney, & B. Bunnell (Eds.), Mesenchymal Stem Cells: Methods and Protocols (Vol. 449, pp. 45-57). United States: Humana Press. DOI Scopus43 Europe PMC27
2008	Gronthos, S., & Zannettino, A. (2008). Potential of Bone Marrow Stromal Stem Cells to Repair Bone Defects and Fractures. In P. S. Koka (Ed.), Progress in Stem Cell Research (pp. 47-62). New York: Nova Science Publishers.
2005	Zannettino, A., Farrugia, A., To, L., & Atkins, G. (2005). An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors. In R. Brown, & P. Joy Ho (Eds.), Multiple Myeloma: Methods and Protocols (Vol. 113, pp. 245-256). Totowa, New Jersey: Humana Press. DOI Scopus3

Conference Papers

Year	Citation
2018	Camp, E., Anderson, P., Zannettino, A., & Gronthos, S. (2018). Inhibition of tyrosine kinase receptor C-ROS-1 as a novel treatment for patients with TWIST haploinsufficiency induced craniosynostosis. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 33 (pp. 424). Montreal, CANADA: WILEY.
2018	Tangseefa, P., Martin, S. K., Wilczek, V., Baldock, P., Proud, C. G., Fitter, S., & Zannettino, A. C. (2018). Metabolic and reproductive abnormalities in mice with impaired skeletal-mTORC1 function mirror a dietary restriction phenotype. In CLINICAL ENDOCRINOLOGY Vol. 89 (pp. 19). Perth, AUSTRALIA: WILEY.
2017	Zeissig, M. N., Hewett, D. R., Martin, S., Mrozik, K. M., Cheong, C. M., Diamond, P., . . . Zannettino, A. C. (2017). HIF-2 alpha Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
2016	Asari, K., Heatley, S. L., Sadras, T., Leclercq, T. M., Fitter, S., Kok, C. H., . . . White, D. L. (2016). In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance Implications for Targeted Therapy. In BLOOD Vol. 128 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY.
2016	Ebert, L., Tan, L., Min, K., Cockshell, M., Johan, M., Parham, K., . . . Bonder, C. (2016). Desmoglein 2 (DSG2) is a novel surface marker of endothelial and haematopoietic progenitor cells, and plays a critical role in neoangiogenesis. In EUROPEAN JOURNAL OF IMMUNOLOGY Vol. 46 (pp. 309). Melbourne, AUSTRALIA: WILEY-BLACKWELL.
2016	Nguyen, T., Arthur, A., Purton, L., Hayball, J., Zannettino, A., Paton, S., . . . Gronthos, S. (2016). EphB4 enhances bone marrow stromal stem cell-mediated support of haematopoiesis. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 173 (pp. 30). British Soc Haematol, Glasgow, SCOTLAND: WILEY-BLACKWELL.
2014	Vandyke, K., Mrozik, K. M., Cheong, C. M., Chow, A. W., Kok, C. H., Blaschuk, O., . . . Zannettino, A. C. (2014). Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. In BLOOD Vol. 124 (pp. 3 pages). San Francisco, CA: AMER SOC HEMATOLOGY.
2013	Forristal, C. E., Helwani, F., Martin, S., Nowlan, B., Winkler, I. G., Zannettino, A., & Levesque, J. -P. (2013). Hypoxia Inducible Factor (HIF)-2 alpha Enhances Proliferation Of Malignant Hematopoietic Cells In The Hypoxic Malignant Bone Marrow. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY. WoS1
2013	Noll, J., Williams, S., Vandyke, K., Kok, C., & Zannettino, A. (2013). IDENTIFICATION AND CHARACTERISATION OF THE ROLE OF SAMSN1 GENE EXPRESSION IN A MURINE MODEL OF MYELOMA AND MYELOMA PATIENTS. In HAEMATOLOGICA Vol. 98 (pp. 316). FERRATA STORTI FOUNDATION.
2013	Noll, J., Williams, S., Tong, C., Wang, H., Purton, L., Farrugia, A., . . . Zannettino, A. (2013). MYELOMA PLASMA CELLS ALTER THE BONE MICROENVIRONMENT BY STIMULATING AN INCREASE IN MESENCHYMAL STEM CELLS: A COMPARATIVE STUDY OF MYELOMA PATIENT- AND MURINE MODEL-DERIVED MESENCHYME. In HAEMATOLOGICA Vol. 98 (pp. 95). FERRATA STORTI FOUNDATION.
2011	Zannetino, A. (2011). PATHOPHYSIOLOGY OF BONE DISEASE IN MULTIPLE MYELOMA. In OSTEOPOROSIS INTERNATIONAL Vol. 22 (pp. S508). Gold Coast, AUSTRALIA: SPRINGER LONDON LTD.
2011	Arthur, A., Panagopoulos, R., Cooper, L., Zannettino, A., Koblar, S., Sims, N., . . . Gronthos, S. (2011). THE ROLE OF EPHB/EPHRINB MOLECULES IN FRACTURE REPAIR. In OSTEOPOROSIS INTERNATIONAL Vol. 22 (pp. S523). Gold Coast, AUSTRALIA: SPRINGER LONDON LTD.
2011	Zinonos, I., Labrinidis, A., Liapis, V., Hay, S., Diamond, P., Findlay, D., . . . Evdokiou, A. (2011). Local production of osteoprotegerin by breast cancer cells inhibits cancer-induced osteolysis and intra-osseous tumour burden but fails to restrain extra-medullary tumour growth. In BONE Vol. 48 (pp. S256). Athens, GREECE: ELSEVIER SCIENCE INC. DOI
2010	Nath, S. V., Tamblyn, M., Telfer, S., Henwood, T., Gilham, P., Story, C., . . . Revesz, T. (2010). Ethylene Diamine Tetra Acetic Acid (EDTA) Decalcification of Paediatric Bone Marrow Trephines In a Diagnostic Laboratory. In BLOOD Vol. 116 (pp. 1062). Orlando, FL: AMER SOC HEMATOLOGY.
2009	McCarty, R., Gronthos, S., Zannettino, A., Foster, B., & Xian, C. (2009). Characterisation of ovine bone marrow derived mesenchymal stromal/stem cells and autologous application to growth plate cartilage defect. In BONE Vol. 45 (pp. S106-S107). Cambridge, ENGLAND: ELSEVIER SCIENCE INC. DOI
2009	McCarty, R., Gronthos, S., Zannettino, A., Foster, B., & Xian, C. (2009). Characterisation of ovine bone marrow derived mesenchymal stem cells and autologous application to growth plate cartilage defect. In BONE Vol. 44 (pp. S159). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC. DOI
2009	Macsai, C., Hopwood, B., Zannettino, A., Scherer, M., Foster, B., & Xian, C. (2009). Micro-CT and micro-array analyses of growth plate cartilage injury responses and bony repair. In BONE Vol. 44 (pp. S152). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC. DOI
2009	Psaltis, P. J., Worthley, S. G., See, F., Itescu, S., Martens, T., Gronthos, S., & Zannettino, A. (2009). Enrichment for Stro-1 Enhances Paracine-mediated Cardiovascular Repair From Human Bone Marrow Mesenchymal Cells. In CIRCULATION Vol. 120 (pp. S821). Orlando, FL: LIPPINCOTT WILLIAMS & WILKINS.
2009	Zinonos, I., Labrinidis, A., Liapis, V., Hay, S., Lee, M., Ponomarev, V., . . . Evdokiou, A. (2009). Apomab, a fully human agonistic DR5 monoclonal antibody inhibits tumour growth and osteolysis in murine models of breast cancer development and progression. In BONE Vol. 44 (pp. S54). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC. DOI
2009	Psaltis, P. J., Carbone, A., Manavis, J., Jantzen, T., Lau, D., Sanders, P., . . . Worthley, S. G. (2009). Catheter-based Electromechanical Mapping Accurately Characterizes Segmental Distribution of Left Ventricular Fibrosis in Nonischemic Cardiomyopathy. In CIRCULATION Vol. 120 (pp. S906). Orlando, FL: LIPPINCOTT WILLIAMS & WILKINS.
2009	Psaltis, P. J., Zannettino, A., Carbone, A., Manavis, J., Williams, K., Jantzen, T., . . . Worthley, S. G. (2009). Cardiac Repair With Transendocardial Injection of Allogeneic Mesenchymal Precursor Cells for Nonischemic Cardiomyopathy. In CIRCULATION Vol. 120 (pp. S827). Orlando, FL: LIPPINCOTT WILLIAMS & WILKINS.
2009	Gronthos, S., Isenmann, S., Arthur, A., Zannettino, A., Shi, S., & Glackin, C. (2009). The role of Twist-1 and-2 in the maintenance of mesenchymal stromal/stem cells. In BONE Vol. 44 (pp. S146). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC. DOI
2009	Engler, J. R., Frede, A., Saunders, V. A., Zannettino, A. C. W., White, D. L., & Hughes, T. P. (2009). OCT-1 Activity in CML CD34+Cells Is Not Predictive of Molecular Response to Imatinib Treatment in CP-CML Patients, Despite the Strong Predictive Value of MNC OCT-1 Activity. In BLOOD Vol. 114 (pp. 861). New Orleans, LA: AMER SOC HEMATOLOGY.
2008	Martin, S., Diamond, P., To, L., Pect, D., Gronthos, S., & Zannettino, A. (2008). CXCL12 Expression Is Regulated by HIF-2a in Multiple Myeloma Plasma Cells. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 23 (pp. S262). Montreal, CANADA: AMER SOC BONE & MINERAL RES.
2008	Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Farrugia, A. N., To, L. B., . . . Zannettino, A. C. W. (2008). Dasatinib (Sprycel (TM)) Inhibits Oteoclast Activity in Vitro and in Vivo Via a C-Fms-Dependent and C-Src-Independent Mechanism. In BLOOD Vol. 112 (pp. 1102-1103). San Francisco, CA: AMER SOC HEMATOLOGY.
2008	Engler, J. R., Frede, A., Zannettino, A. C., White, D. L., & Hughes, T. P. (2008). Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients. In BLOOD Vol. 112 (pp. 80). San Francisco, CA: AMER SOC HEMATOLOGY. WoS2
2008	Freeman, L. M., Petcu, E., Smith, R., Salajegheh, A., Diamond, P., Zannettino, A. C. W., . . . Vuckovic, S. (2008). Depletion of Host CD122(+) Cells Facilitates Widespread Skeletal Multiple Myeloma Engraftment in NOD/SCID Recipients.. In BLOOD Vol. 112 (pp. 945). San Francisco, CA: AMER SOC HEMATOLOGY.
2008	Diamond, P., Labrinidis, A., Martin, S., Gronthos, S., To, L., Fuji, N., . . . Zannettino, A. (2008). Elevated Serum Levels of CXCL12 Is Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 23 (pp. S262). Montreal, CANADA: AMER SOC BONE & MINERAL RES.
2007	Martin, S., Dewar, A., Farrugia, A., Horvath, N., Gronthos, S., To, L., & Zannettino, A. (2007). Tumour angiogenesis correlates with plasma levels of CXCL12 in patients with multiple myeloma. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 125-126). Kos Isl, GREECE: FERRATA STORTI FOUNDATION.
2007	See, F., Seki, T., Psaltis, P., Martens, T., Gronthos, S., Worthley, S., . . . Itescu, S. (2007). Human stroll mesenchymal precursor cells induce proliferative effects on vascular smooth muscle cells and endothelium via P13 kinase dependent pathways. In CIRCULATION Vol. 116 (pp. 104). Orlando, FL: LIPPINCOTT WILLIAMS & WILKINS.
2007	Diamond, P., Labrinidis, A., Martin, S., Farrugia, A., Gronthos, S., To, L., . . . Zannettino, A. (2007). CXCL12 stimulates osteoclastic bone resorption in a novel mouse model of human multiple myeloma. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 130). Kos Isl, GREECE: FERRATA STORTI FOUNDATION.
2006	White, D., Dang, P., Venables, A., Saunders, V., Zrim, S., Zannettino, A., . . . Hughes, T. (2006). ABCB1 overexpression may predispose imatinib treated CML patients to the development of Abl kinase domain mutations, and may be an important contributor to acquired resistance.. In BLOOD Vol. 108 (pp. 608A). Orlando, FL: AMER SOC HEMATOLOGY. WoS2
2006	White, D., Saunders, V., Dang, P., Venables, A., Zrim, S., Reynolds, J., . . . Hughes, T. (2006). Molecular response to imatinib is dependent on dose in CML patients with low OCT-1 influx activity. Patients with high activity may respond equally well to standard or increased dose imatinib.. In BLOOD Vol. 108 (pp. 222A). Orlando, FL: AMER SOC HEMATOLOGY.
2005	Atkins, G., Kostakis, P., Vincent, C., Farrugia, A., Findlay, D., Evdokiou, A., & Zannettino, A. (2005). RANK expression in normal and malignant haemopoietic cells: A monoclonal antibody study.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 20 (pp. S146). Nashville, TN: AMER SOC BONE & MINERAL RES.
2005	White, D., Saunders, V., Engler, J., Dang, P., Zannettino, A., Cambareri, A., . . . Hughes, T. (2005). Low baseline intrinsic sensitivity to imatinib (high IC50) in CML patients is due to reduced Oct-1 mediated influx. Intrinsic sensitivity to AMN107 does not correlate with that of imatinib and uptake of AMN107 is not Oct-1 mediated.. In BLOOD Vol. 106 (pp. 315A). Atlanta, GA: AMER SOC HEMATOLOGY.
2005	Zannettino, A., Kortesidis, A., Farrugi, A., & Gronthos, S. (2005). The role of stromal derived factor-1 alpha in bone remodelling.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 20 (pp. S368). Nashville, TN: AMER SOC BONE & MINERAL RES.
2005	Kostakis, P., Atkins, G., Vincent, C., Farrugia, A., Findlay, D., Evdokiou, A., & Zannettino, A. (2005). RANK expression in normal and malignant cells: a monoclonal antibody study. In Journal of Bone and Mineral Research Vol. 20 (pp. SA-259.). Nashville, Tennessee: American Society for Bone and Mineral Research.
2004	Atkins, G., Anderson, P., Welldon, K., Zannettino, A., Morris, H., & Findlay, D. (2004). Vitamin D metabolism in human osteoblasts. In Journal of Bone and Mineral Research Vol. 19 (pp. SA-587). Seattle, Washington: American Society for Bone and Mineral Research.
2004	Martens, T., Schuster, M., See, F., Xydas, S., Hefti, M., Gronthos, S., . . . Itescu, S. (2004). Human mesenchymal precursors induce myocardial arteriogenesis and global functional recovery after myocardial ischemia. In CIRCULATION Vol. 110 (pp. 70). New Orleans, LA: LIPPINCOTT WILLIAMS & WILKINS.
2004	Atkins, G., Anderson, P., Welldon, K., Zannettino, A., Morris, H., & Findlay, D. (2004). Vitamin D metabolism in human osteoblasts.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 19 (pp. S204). Seattle, WA: AMER SOC BONE & MINERAL RES.
2003	Pan, B., To, L., Farrugia, A., Kostakis, P., Atkins, G., Findlay, D., & Zannettino, A. (2003). Multiple myeloma-derived pro-inflammatory cytokines enhance osteoclastogenesis by increasing the number of RANKL-expressing STRO-1 positive osteoprogenitor cells.. In BLOOD Vol. 102 (pp. 370B). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
2003	Atkins, G., Anderson, P., Morris, H., Zannettino, A., Kostakis, P., & Findlay, D. (2003). The expression of 25-hydroxyvitamin D 24-hydroxylase and 25-hydroxyvitamin D 1 alpha-hydroxylase in human osteoblasts.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 18 (pp. S409). MINNEAPOLIS, MINNESOTA: AMER SOC BONE & MINERAL RES.
2003	Zreiqat, H., Howlett, C., Zannettino, A., Evans, P., Knabe, C., Schulze-Tanzil, G., & Shakibae, G. (2003). Surface modification of bioceramics affect osteoblastic cells response. In B. BenNissan, D. Sher, & W. Walsh (Eds.), Key Engineering Materials Vol. 240-242 (pp. 707-710). UNIV TECHNOL, SYDNEY, AUSTRALIA: TRANS TECH PUBLICATIONS LTD. DOI Scopus4 WoS3
2003	Kostakis, P., Atkins, G., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., . . . Zannettino, A. (2003). The relationship between RANKL expression and osteoblast differentiation in human osteoblasts. In 30th European Symposium on Calcified Tissues, 8-12 May 2003 Vol. Italy (pp. 314-468). Rome, Italy. DOI
2002	Atkins, G., Zannettino, A., Kostakis, P., Pan, B., Farrugia, A., Evdokiou, A., & Findlay, D. (2002). Evidence for the maturation-dependent expression of an osteoclastogenic phenotype in human osteoblasts.. In Journal of Bone and Mineral Research Vol. 17 (pp. S446.). San Antonio, Texas: American Society for Bone and Mineral Research.
2002	Atkins, G., Pan, B., Findlay, D., To, L., Evdokiou, A., Labrinidis, A., . . . Zannettino, A. (2002). Zoledronate is anabolic for human osteoblast-like cells. In Journal of Bone and Mineral Research Vol. 17 (pp. S442.). San Antonio, Texas: American Society for Bone and Mineral Research.

Conference Items

Year	Citation
2018	Cakouros, D., Hemming, S., Pribadi, C., Zannettino, A., & Gronthos, S. (2018). EPIGENETIC ENZYMES AND THEIR EMERGING ROLE IN MESENCHYMAL STEM CELL LINEAGE DETERMINATION. Poster session presented at the meeting of JOURNAL OF GENE MEDICINE. Univ Technol Sydney, Sydney, AUSTRALIA: WILEY.
2017	Liapis, V., Zinonos, I., Labrinidis, A., Hay, S., Ponomarev, V., Panagopoulos, V., . . . Evdokiou, A. (2017). The hypoxia activated pro-drug evofosfamide exhibits tumour suppressive activity and synergy with chemotherapy against primary and metastatic breast cancers. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. SPANDIDOS PUBL LTD.
2017	Asari, K., Sadras, T., Srihari, S., Fitter, S., An, J., Zannettino, A. C., . . . White, D. L. (2017). in vitro Modelling of Ph-like ALL Fusions Uncovers Novel Kinase-domain Mutations as a Mode of TKI-resistance and Potential Consequence of Targeted TKI Therapy. Poster session presented at the meeting of ANZCHOG.
2016	Asari, K., Heatley, S., Leclercq, T., Fitter, S., Zannettino, A., Hughes, T., & White, D. L. (2016). In vitro Modelling of Therapeutic Resistance to Elucidate Mechanisms of TKI-Resistant High-Risk ALL. Poster session presented at the meeting of .. Noosa, QLD.
2016	Asari, K., Heatley, S., Leclercq, T., Fitter, S., Kok, C. H., Zannettino, A., . . . White, D. L. (2016). Investigating Modes of Therapeutic Resistance via In Vitro Modelling of TKI-resistant High-Risk Philadelphia-chromosome-positive and Philadelphia-chromosome-like Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster Session. Adelaide, SA.
2015	Freeman, B., Kuliwaba, J., Zarrinkalam, M., Jones, C., Shu, C., Colloca, C., . . . Howell, S. (2015). ALLOGENEIC MESENCHYMAL STEM CELLS IMPROVE INDICES OF LUMBAR INTERVERTEBRAL DISC DEGENERATION WITHOUT SITE SPECIFICITY OF INJECTION IN AN OVINE MODEL. Poster session presented at the meeting of OSTEOARTHRITIS AND CARTILAGE. Seattle, WA: ELSEVIER SCI LTD. DOI WoS1
2014	Cheung, K. C., Hewett, D., Yeung, D., Tan, C. W., To, L. B., & Zannettino, A. (2014). THE ROLE OF MERTK IN THE PROGRESSION OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) TO MYELOMA (MM). Poster session presented at the meeting of HAEMATOLOGICA. Milan, ITALY: FERRATA STORTI FOUNDATION.
2013	Forristal, C., Helwani, F., Nowlan, B., Martin, S., Zannetino, A., & Levesque, J. -P. (2013). HYPOXIA INDUCIBLE FACTOR (HIF)-2 alpha ENHANCES PROLIFERATION OF MALIGNANT HAEMATOPOIETIC CELLS IN THE HYPOXIC MALIGNANT BONE MARROW. Poster session presented at the meeting of EXPERIMENTAL HEMATOLOGY. Vienna, AUSTRIA: ELSEVIER SCIENCE INC. DOI
2013	Dharmapatni, A., Coleman, R., Lorimer, M., Zannettino, A., Weedon, H., Wechalekar, M., . . . Crotti, T. (2013). Relationship between Soluble OSCAR and Disease Activity: A 12 Month Study of Newly Diagnosed RA Patients. Poster session presented at the meeting of JOURNAL OF BONE AND MINERAL RESEARCH. Baltimore, MD: WILEY-BLACKWELL.
2012	Crotti, T., Alias, E., Dharmapatni, A., Weedon, H., Zannettino, A., & Smith, M. (2012). EVIDENCE THAT VASCULAR EXPRESSION OF THE ITAM RECEPTOR, OSCAR, IN ACTIVE RHEUMATOID ARTHRITIS IS MODULATED BY INFLAMMATORY MEDIATORS. Poster session presented at the meeting of INTERNAL MEDICINE JOURNAL. WILEY-BLACKWELL.
2012	Frith, J. E., Menzies, D. J., Cameron, A. R., Gronthos, S., Zannettino, A. C. W., Ghosh, P., & Cooper-White, J. J. (2012). A novel injectable hydrogel for intervertebral disc regeneration. Poster session presented at the meeting of JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE. WILEY-BLACKWELL.
2008	Vandyke, K., Dewar, A. L., Davis, A. N., Fiuer, S., Hughes, T. P., To, L. B., & Zannettino, A. C. W. (2008). The tyrosine kinase inhibitor dasatinib decreases osteoclast formation and activity in vitro. Poster session presented at the meeting of 30th Annual Meeting of the American Society for Bone and Mineral Research, as published in Journal of Bone and Mineral Research. Montreal, Canada: Wiley. DOI
2003	Atkins, G., Anderson, P., Morris, H., Zannettino, A., Kostakis, P., & Findlay, D. (2003). The expression of 25-hydroxyvitaminD 24-hydroxylase and 25-hydroxyvitaminD 1 alpha-hydroxylase in human osteoblasts. Poster session presented at the meeting of Journal of Bone Mineral Research. Minnesota, USA.
2003	Anderson, P., Atkins, G., Morris, H., Kostakis, P., Findlay, D., & Zannettino, A. (2003). The expression of 25-hydroxyvitaminD 24-hydroxylase and 25-hydroxyvitaminD 1 alpha-hydroxylase in human osteoblasts.. Poster session presented at the meeting of Calcified Tissue International. Rome, Italy: Springer.

Datasets

Year	Citation
2004	Hu, Y., Atkins, G., Zhou, H., Myers, D., Quinn, J., Ly, C., . . . Ng, K. (2004). NM_001004419 Homo sapiens C-type lectin domain family 2, member D (CLEC2D), transcript variant 2, mRNA.
2004	Hu, Y., Atkins, G., Zhou, H., Myers, D., Quinn, J., Ly, C., . . . Ng, K. (2004). NM_013269 Homo sapiens C-type lectin domain family 2, member D (CLEC2D), transcript variant 1, mRNA.
—	Dutta, A., Zannettino, A., Hewett, D., & l.fink@uq.edu.au. (n.d.). ZANNETTINO_EGA DAA_EGAS00001002850.doc. DOI

Research Funding

Since establishing my laboratory in 2000, I have received competitive research funding of more than AUD$15,019,583 and AUD$2,835,000 in infrastructure funding. Of note, as a CI, I have been awarded a total of 19 NHMRC grants valued in excess of AUD$9,725,058, 1 Cancer Australia grant and 1 International Leukemia Lymphoma Society (US) grant. Furthermore, I have received industry funding of AUD$5 million from sources including Mesoblast, Celgene, Novartis, Zimmer and Johnson & Johnson. A list of the NH&MRC, ARC and other awarded grants are provided below.

**Summary of NH&MRC Funding**
Grant Title	Funding	Initiative	Role	First Year Funded	Number of Years	Total Amount ($) of Grant
Targeting skeletal mTORC1 as a novel approach for the treatment of diet-induced insulin resistance	Research Support	Project Grant	CIA	2016	3	586,979.00
Why is the bone marrow a “hot-spot” for myeloma plasma cell metastasis: are there Gremlins in the system?	Research Support	Project Grant	CIA	2016	3	651,979.00
The role of ephrinB1 reverse signalling in osteogenic differentiation during skeletal development and osteoporosis	Research Support	Project Grant	CIB	2015	3	548,347.00
Understanding clonal evolution in multiple myeloma	Research Support	Project Grant	CIA	2014	3	647,111.00
Twist-1 inhibits MSC osteoblast differentiation during osteoporosis	Research Support	Project Grant	CIB	2013	3	466,044.00
Is mTOR a novel target for the treatment of osteoporosis?	Research Support	Project Grant	CIA	2012	3	543,675.00
EphB-ephrinB mediates MSC bone regeneration	Research Support	Project Grant	CIB	2012	3	591,010.00
The Role of Hypoxia and Myeloma Disease Progression	Research Support	Project Grant	CIA	2010	3	594,582.00
Twist-1 Regulation of MSC Growth and Development	Research Support	Project Grant	CIB	2010	3	594,582.00
Novel strategies for the treatment of bone cancer	Research Support	Project Grant	CIC	2009	3	456,304.00
Control of premature bony fusion in skull development	Research Support	Project Grant	CIC	2008	3	555,855.00
Role of TWEAK in bone remodelling	Research Support	Project Grant	CIE	2007	3	566,947.00
The role of factors that regulate early processes of bone cell development	Research Support	Project Grant	CIB	2007	3	485,929.00
Chemokines and Myeloma Disease Progression	Research Support	Project Grant	CIA	2007	3	665,897.00
The role of human osteoblasts in osteoclast formation	Research Support	Project Grant	CIC	2004	3	436,450.00
Skeletal disease mediated by haematological malignancy	Research Support	Project Grant	CIA	2004	3	432,750.00
The cells and molecules involved in the formation and activity of human osteoclasts	Research Support	Project Grant	CID	2001	3	326,036.00
Drug resistance in leukaemia	Research Support	Project Grant	CIC	2001	3	362,545.00
The Molecular Mechanisms of Bone Destruction in Multiple Myeloma	Research Support	Project Grant	CIA	2001	3	212,036.00

Summary of Other Funding
Grant Title	Funding	Source	Role	First Year Funded	Number of Years	Total Amount ($) of Grant
Skeletal endocrine signalling in the regulation of glucose metabolism	Research Support	Australian Research Council	CIA	2016	3	379,400.00
A Tough Resilin based Hydrogel Platform for Repair and Regeneration	Research Support	Australian Research Council	CIB	2016	3	358,000.00
Tyrosine Kinase Inhibition as a Potential Modality to Control Osteolytic Bone Disease: A New Role for Imatinib Mesylate and Second Generation Bcr-Abl Inhibitors	Industry Research Support	Novartis Pharma-ceuticals International	CIA	2007	3	470,000.00
Efficacy of Targeting the mTOR and PI3 Kinase Pathways as a Treatment Modality for Myeloma	Industry Research Support	Novartis Pharma-ceuticals International	CIA	2011	1	65,000.00
Development of a Comprehensive Data Base for Myeloma and Related Disorders	Industry Support	Celgene Australia	CIB	2010	2	120,000.00
Seed Grant for the Establishment of a Multiple Myeloma and Related Disorders Database	Research Support	Cancer Council of South Australia	CIB	2010	1	35,000.00
Abl Kinase Inhibition as a Novel Therapy for Myeloma-Associated Bone Loss	Research Support	Leukemia & Lymphoma Society - TRP	CIA	2009	3	750,000.00
Is elevated N-cadherin expression a poor prognostic indicator in multiple myeloma patients?	Research Support	Cancer Australia and Leukaemia Foundation	CIA	2010	3	528,666.00
Abl Kinase Inhibition as a Novel Therapy for Malignancy-Associated Bone Loss	Research Support	Cancer Council of South Australia	CIA	2009	1	93,000.00
Does Modifying the bone marrow stromal micro-environment alter the disease course of multiple myeloma?	Research Support	Cancer Council of South Australia	CIA	2009	1	99,171.00
Coopertaing genetic changes that drive MM development: the role of SAMSN1 and GLIPR1 tumour suppressor gene	Research Support	Cancer Council of South Australia	CIA	2015	1	75,000.00
Is mTOR a novel target for the treatment of osteoporosis?	Research Support	Research, Robinson Institute Collaborative Grant	CIA	2011	1	75,000.00
Understanding the mechanisms of aberrant bone formation in Saethre-Chotzen syndrome patients with Twist-1 mutations	Research Support	Research, Robinson Institute Collaborative Grant	CIB	2013	1	65,000.00
Understanding the mechanisms of aberrant bone formation in Saethre - Chotzen syndrome patients with Twist-1 mutations	Research Support	Project Grant	CIB	2007	3	485,929.00
Understanding clonal evolution in multiple myeloma	Research Support	Ray and Shirl Norman Trust- HSCGB	CIA	2014	3	300,000.00
South Australian Blood Cancer Tumour Bank	Infra-structure Support	SA Cancer Research, Medvet, Community donor	CID	2013	3	980,000.00
Minimal residual disease (MRD) detection in Multiple Myeloma (MM) patients in complete remission post-autograft: correlation with risk of relapse?	Research Support	SA Pathology RAH Contributing Haematologists’ Committee Fund	CIB	2015	1	30,000.00
Australian Cancer Research Foundation South Australian Innovative Cancer Imaging And Therapeutics Facility	Infra-structure Support	Australian Cancer Research Foundation	CIC	2013	1	1,800,000.00
Bone Marrow Recovery in Acute Lymphoblastic Leukaemia	Research Support	Women’s and Children’s Health Foundation	CIA	2015	2	226,426.00
An improved technology for isolating human adult stem cells for regenerative therapies	Research Support	Adelaide Research and Innovation- Commercial Accelerator Scheme Fund	CIA	2013	1	100,000.00
Can The Level of Stromal-Derived Factor-1 (SDF-1α) In Myeloma Patients Predict if They Will Develop Osteolytic Bone Disease?	Research Support	RAH/IMVS Clinical Research Grants	CIA	2004	1	18, 500
The Identification and Characterization of Novel Regulators of Mesenchymal Stem Cell Differentiation and Lineage Commitment	Industry Support	Zymogenetics Inc., Seattle, Washington	CIA	1999	1	90,000.00
Characterisation of Novel Drug-Resistance Proteins in Human Leukaemic Cells	Industry Support	Medvet Pty Ltd	CIC	2000	1	110,000.00
Novel Interaction of the Epidermal Growth Factor-Like Protein DLK with the Growth Arrest-Specific Gene Product GAS-1: Implications for Adipocyte Differentiation	Research Support	IMVS/RAH Research Fund	CIB	2001	1	11,000.00
Characterisation of RANKL and OPG production by human osteoblastic cells	Industry Support	Ely Lilly	CIB	2002	1	20,000.00
Utilisation of human osteoblast and osteoclast co-culture models to study anti-resorptive and anabolic agents	Industry Support	Ely Lilly	CIC	2004	1	15,000.00
Tantalum and osteointegration	Industry Support	Zimmer	CIC	2002	1	45,000.00
Can The Level of Stromal-Derived Factor-1 (SDF-1α) In Myeloma Patients Predict if They Will Develop Osteolytic Bone Disease?	Research Support	Royal Adelaide Hospital-IMVS Research Fund-Clinical Project Grants	CIA	2004	1	23,500.00
Mechanisms of Increased Microvessel Density (MVD) In Multiple Myeloma	Research Support	IMVS-Contributing Haematologist Committee Fund	CIA	2004	1	36,000.00
The Use of Aptamer-Based technologies to Identify Immuno-dominant Epitopes of Factor VIII Which are Responsible for the Development of Anti-Factor VIII Antibodies (Inhibitors)	Research Support	IMVS-Contributing Haematologist Committee Fund	CIA	2005	1	30,000.00
Can The Level of Stromal-Derived Factor-1 (SDF-1α) In Myeloma Patients Predict if They Will Develop Osteolytic Bone Disease?	Research Support	Cancer Council South Australia	CIA	2005	1	149,416.00
The Efficacy of Mesenchymal Precursor Cells to Repair Cardiac Defects	Industry Support	Angioblast Systems, Ltd	CIA	2003	2	100,000.00
Development of Strategies For The Therapeutic Use of Mesenchymal Precursor Cells For Cartilage Repair	Industry Support	Mesoblast Ltd	CIB	2006	2	320,692.00
Evaluation of the safety and efficacy of Allogeneic Mesenchymal Progenitor Cells (MPC) for the repair of critical size defects in an ovine tibial model	Industry Support	Mesoblast Ltd	CIB	2006	1	725,000.00
A Preclinical trial of the potential for cultured mesenchymal precursor cells to restore extracellular matrix and normal mechanical function to degenerate intervertebral discs	Industry/ Research Support	Mesoblast Ltd/ AusIndustry Grant	CIC	2006	2	794,850.00
Research and Services Agreement	Industry/ Research Support	Angioblast Ltd/ Mesoblast Ltd	CIB	2003	3	300,000.00
BIR (Bortezomib Induction and Reinduction) Study	Clinical Trial and Research Support	Johnson & Johnson	CIB	2006	2	445,875.00
Kodak chemiluminescence and gel imaging system (4000MM Pro Image Station).	Infra-structure Support	University of Adelaide/NH&MRC Equipment Grant	CIF	2008	1	55,000.00

As a former fulltime Medical Scientist in the Department of Haematology, SA Pathology/Institute of Medical and Veterinary Science and Level E Affiliate Titleholder in the School of Medicine, Faculty of Health Science, University of Adelaide, I provided leadership in teaching and supervision in my daily interactions with post-doctoral scientists, research assistants, undergraduate, graduate and post-graduate students. Furthermore, during this period, I provided numerous guest lectures (BBTech students, Uni SA; BHlthSci and MBBS, Uni Adelaide) and successfully mentored numerous honours, masters, PhD and medical students (as part of Department of Medicine’s 4th Year Research Program).

In addition to graduate and post-graduate teaching, since joining the University of Adelaide as Professor of Experimental Haematology, I present undergraduate lectures in courses offered by the Faculty of Health Science ([FHS] Medicine, Physiology, Anatomy and Pathology and Dentistry), Faculty of Science ([FS] Masters program, stem cells) and the University of Sydney (tissue engineering). I provide Honours workshops relating to thesis writing, career opportunities and career development. I also host Physiology III (BHlthSci, FHS) and Principals and Practice of Research III (BSc Advanced, FS) students in my laboratory for small group discovery and research training.

Expand

Current Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2018	Principal Supervisor	The Yin and Yang of Myeloma Development: The Role of the Bone Marrow Microenvironment in Plasma Cell Dormancy and Activation	Master of Philosophy (Medical Science)	Master	Full Time	Miss Natalya Plakhova
2017	Principal Supervisor	Investigation of the competing effects of the CXCL12/CXCR4 and CCL3/CCR1 chemokine axes in the dissemination and migration of multiple myeloma plasma cells	Doctor of Philosophy	Doctorate	Full Time	Miss Mara Natasha Zeissig
2017	Co-Supervisor	Elucidating the Roles HIFI/HIFI2 on Multiple Myeloma Using an Inducible CRISPR/Cas9 System	Master of Philosophy	Master	Full Time	Mr Yu Chinn Joshua Chey
2017	Principal Supervisor	The role of osteoblast-mTORC1 in the regulation of glucose metabolism and male fertility	Doctor of Philosophy	Doctorate	Full Time	Miss Pawanrat Tangseefa
2017	Principal Supervisor	Investigating the Role of Resident Bone Macrophages in Multiple Myeloma	Doctor of Philosophy	Doctorate	Full Time	Mrs Khatora Shanae Opperman
2015	Principal Supervisor	The Molecular and Cellular Characterisation of the Cancer Stem Cell Niche in Multiple Myeloma	Doctor of Philosophy	Doctorate	Full Time	Ms Kimberley Claire Evans
2015	Co-Supervisor	High Cell Density Proliferation of Human Induced Pluripotent Stem Cells	Doctor of Philosophy	Doctorate	Full Time	Mr Jiabin Zhang
2015	Principal Supervisor	Cooperating Genetic Changes that Drive Myeloma Development - The Role of the Samsn 1 and GLIPRI Tumour Suppressor Genes	Doctor of Philosophy	Doctorate	Full Time	Ms Natasha Friend

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2014 - 2018	Principal Supervisor	A Genomic Approach Towards an Understanding of Clonal Evolution and Disease Progression in Multiple Myeloma	Doctor of Philosophy	Doctorate	Full Time	Ankit Kumar Dutta
2013 - 2017	Principal Supervisor	The Role of TWIST1 in Multiple Myeloma	Doctor of Philosophy	Doctorate	Full Time	Miss Chee Man Cheong
2012 - 2018	Principal Supervisor	N-cadherin: Regulation, Role and Therapeutic Targeting in Multiple Myeloma	Doctor of Philosophy	Doctorate	Full Time	Mr Krzysztof Mrozik
2011 - 2014	Co-Supervisor	Mesenchymal Stem Cells for the Treatment of Myocardial Infarction-Induced Ventricular Dysfunction	Doctor of Philosophy	Doctorate	Full Time	Dr James David Richardson
2011 - 2018	Co-Supervisor	Investigating the Role of HIF-1 and HIF-2 Transcription Factors in Multiple Myeloma	Doctor of Philosophy	Doctorate	Full Time	Miss Natalia Magdalena Martin
2010 - 2018	Principal Supervisor	The Role of mTORC1 in Mesenchymal Stem Cell Fate Determination, Osteoblast Differentiation and Skeletal Development	Doctor of Philosophy	Doctorate	Part Time	Ms Mary Patricia Matthews
2009 - 2013	Co-Supervisor	The Role of TWIST-1 in the Regulation of Mesenchymal Stem Cell Growth, Fracture Repair and Bone Loss	Doctor of Philosophy	Doctorate	Full Time	Mr Lachlan Cooper
2007 - 2011	Co-Supervisor	Cell Lineage, Cell Maturity and BCR-ABL: Factors Which Influence Imatinib Uptake in Chronic Myeloid Leukaemia	Doctor of Philosophy	Doctorate	Full Time	Ms Jane Engler
2007 - 2010	Principal Supervisor	The Effects of Tyrosine Kinase Inhibition on Bone Remodelling	Doctor of Philosophy	Doctorate	Full Time	Dr Kate Vandyke
2006 - 2010	Co-Supervisor	The Cardiovascular Reparative Properties of Bone Marrow Mesenchymal Precursor Cells	Doctor of Philosophy	Doctorate	Full Time	APrf Peter Psaltis
2005 - 2009	Principal Supervisor	Molecular and Cellular Mechanisms of Increased Angiogenesis in Multiple Myeloma: A Role for CXCL12	Doctor of Philosophy	Doctorate	Full Time	Mrs Sally Martin
2005 - 2012	Co-Supervisor	Cellular and Molecular Mechanisms Involved in the Repair of the Injured Growth Plate in Young Rats	Doctor of Philosophy	Doctorate	Full Time	Ms Carmen Macsai
2004 - 2008	Co-Supervisor	Factors which Impact on the Response of CML Patients to ABL Kinase Inhibitor Therapy: A Study of Imatinib and Nilotinib	Doctor of Philosophy	Doctorate	Part Time	Prof Deborah Lee White
2002 - 2004	Principal Supervisor	Mechanisms of Skeletal Disease Mediated by Haematological Malignancies	Doctor of Philosophy	Doctorate	Full Time	Miss Beiqing Pan
2001 - 2002	Principal Supervisor	CLINICAL MEDICINE	Master of Medical Science	Master	Full Time	Miss Beiqing Pan

Expand

Board Memberships

Date	Role	Board name	Institution name	Country
2016 - ongoing	—	ARCPOH Expert Advisory Committee	University of Adelaide	—
2015 - ongoing	Member	Board of Directors	Colgate Australian Clinical Dental Research Centre, University of Adelaide	Australia
2014 - ongoing	Member	Advisory Board	Robinson Research Institute (RRI), University of Adelaide	Australia

Committee Memberships

Date	Role	Committee	Institution	Country
2016 - ongoing	Member	National Health and Medical Research Council	NHMRC Assigners Academy	Australia
2015 - ongoing	Member	National Health and Medical Research Council	NHMRC Assigners Academy	Australia
2014 - 2015	Chair	Research Committee, School of Medical Science	University of Adelaide	Australia
2012 - ongoing	Member	Bioscience Pillar Committee	South Australian Health and Medical Research Institute (SAHMRI)	Australia
2012 - ongoing	Member	Cell Reprogramming Australia (CRA)	—	—
2012 - ongoing	Member	Robinson Institute Transition Management Committee	University of Adelaide	Australia
2012 - ongoing	Member	Leukaemia Foundation National Research Program Assessment Panel	Leukaemia Foundation	Australia
2010 - 2015	Member	Scientific Advisory Committee	Bone Health Foundation	Australia
2010 - ongoing	Member	Centre for Personalised Cancer Medicine	The University of Adelaide	Australia
2010 - 2013	Member	Fellowships and Scholarships Committee	Leukaemia Foundation of Australia	Australia
2009 - 2012	Member	Medical Assessment Classification Committee	SA Pathology	—
2007 - 2012	Co-Chair	Institutional Biosafety Committee	SA Pathology/Institute of Medical and Veterinary Science	Australia
2006 - ongoing	Member	Medical and Scientific Advisory Group	Australian Myeloma Foundation	Australia

Memberships

Date Role Membership Country
2010 - ongoing Member Centre for Cancer Biology, SA Pathology Australia
2010 - ongoing Member Centre for Stem Cell Research, University of Adelaide Australia
Consulting/Advisories

Date Institution Department Organisation Type Country
2013 - ongoing CSIRO — — Australia
2010 - ongoing South Australian Health and Medical Research Institute — — Australia

Date	Role	Membership	Country
2010 - ongoing	Member	Centre for Cancer Biology, SA Pathology	Australia
2010 - ongoing	Member	Centre for Stem Cell Research, University of Adelaide	Australia

Date	Institution	Department	Organisation Type	Country
2013 - ongoing	CSIRO	—	—	Australia
2010 - ongoing	South Australian Health and Medical Research Institute	—	—	Australia

Offices Held

Date	Office Name	Institution	Country
2014 - ongoing	NHMRC Assigners Academy	National Health and Medical Research Council	Australia
2012 - ongoing	Cancer Biology and Oncology GRP	National Health and Medical Research Council	Australia
2011 - ongoing	Reshaping the Robinson Task Force, Robinson Institute	University of Adelaide	Australia
2010 - ongoing	Oncology GRP	National Health and Medical Research Council	Australia
2006 - ongoing	Cell Biology GRP	National Health and Medical Research Council	Australia

Position: Professor of Experimental Haematology
Phone: 81284390
Email: andrew.zannettino@adelaide.edu.au
Campus: North Terrace West
Building: SAHMRI, floor 5
Room: 5 321
Org Unit: Medical Sciences

Professor Andrew Zannettino

Research Interests

Current projects are focused on

Research Leadership

Myeloma and Bone Cancer Research

The MRL has made a significant contribution to the field in relation to

Therapeutic Use of Mesenchymal Progenitor Cells

Research Collaborations

Research Output

Presentations

Additional Evidence of Research Leadership

Clinical Outcomes of Research

Patents

Appointments

Awards and Achievements

Education

Research Interests

Journals

Book Chapters

Conference Papers

Conference Items

Datasets

Research Funding

Current Higher Degree by Research Supervision (University of Adelaide)

Past Higher Degree by Research Supervision (University of Adelaide)

Board Memberships

Committee Memberships

Memberships

Consulting/Advisories

Offices Held

Connect With Me

External Profiles

Other Links